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Background: Preliminary studies using the FENIX™ (Torax Medical, Minneapolis, MN, USA) magnetic
sphincter augmentation device suggest that it is safe to use for the treatment of adult faecal
incontinence, but efficacy data are limited.
Objective: To compare FENIX with sacral nerve stimulation for the treatment of adult faecal
incontinence in terms of safety, efficacy, quality of life and cost-effectiveness.
Design, setting and participants: Multicentre, parallel-group, unblinded, randomised trial comparing
FENIX with sacral nerve stimulation in participants suffering moderate to severe faecal incontinence.
Interventions: Participants were randomised on an equal basis to either sacral nerve stimulation or
FENIX. Follow-up occurred 2 weeks postoperatively and at 6, 12 and 18 months post randomisation.
Main outcome and measure: The primary outcome was success, defined as device in use and
≥ 50% improvement in Cleveland Clinic Incontinence Score at 18 months post randomisation.
Secondary outcomes included complication rates, quality of life and cost-effectiveness. Between
30 October 2014 and 23 March 2017, 99 participants were randomised across 18 NHS sites
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(50 participants to FENIX vs. 49 participants to sacral nerve stimulation). The median time from
randomisation to FENIX implantation was 57.0 days (range 4.0–416.0 days), and the median time
from randomisation to permanent sacral nerve stimulation was 371.0 days (range 86.0–918.0 days).
A total of 45 out of 50 participants underwent FENIX implantation and 29 out of 49 participants
continued to permanent sacral nerve stimulation. The following results are reported, excluding
participants for whom the corresponding outcome was not evaluable. Overall, there was success
for 10 out of 80 (12.5%) participants, with no statistically significant difference between the two
groups [FENIX 6/41 (14.6%) participants vs. sacral nerve stimulation 4/39 (10.3%) participants].
At least one postoperative complication was experienced by 33 out of 45 (73.3%) participants in
the FENIX group and 9 out of 40 (22.5%) participants in the sacral nerve stimulation group. A total
of 15 out of 50 (30%) participants in the FENIX group ultimately had to have their device explanted.
Slightly higher costs and quality-adjusted life-years (incremental = £305.50 and 0.005, respectively)
were observed in the FENIX group than in the sacral nerve stimulation group. This was reversed
over the lifetime horizon (incremental = –£1306 and –0.23 for costs and quality-adjusted life-years,
respectively), when sacral nerve stimulation was the optimal option (net monetary benefit = –£3283),
with only a 45% chance of FENIX being cost-effective.
Limitations: The SaFaRI study was terminated in 2017, having recruited 99 participants of the target
sample size of 350 participants. The study is, therefore, substantially underpowered to detect differences
between the treatment groups, with significant uncertainty in the cost-effectiveness analysis.
Conclusions: The SaFaRI study revealed inefficiencies in the treatment pathways for faecal incontinence,
particularly for sacral nerve stimulation. The success of both FENIX and sacral nerve stimulation was much
lower than previously reported, with high postoperative morbidity in the FENIX group.
Future work: Further research is needed to clarify the treatment pathways for sacral nerve
stimulation and to determine its true clinical and cost-effectiveness.
Trial registration: Current Controlled Trials ISRCTN16077538.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 18.
See the NIHR Journals Library website for further project information.
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Faecal incontinence is a distressing condition for patients, and surgery is recommended if symptomsare having an effect on quality of life. One of the treatments recommended for faecal incontinence
by the National Institute for Health and Care Excellence is sacral nerve stimulation, which aims to
improve continence by stimulating the nerves to the back passage. A newer treatment involves surgery
to implant a string of magnetic beads around the anal canal using the FENIX™ device (Torax Medical,
Minneapolis, MN, USA). The aim of this study was to assess the benefits and risks of the FENIX device
compared with sacral nerve stimulation.
The SaFaRI study aimed to recruit 350 participants with faecal incontinence, but was stopped early
because of the manufacturer withdrawing the FENIX device for strategic reasons. In total, we recruited
99 participants. Fifty participants were allocated to receive the FENIX device and 49 participants were
allocated to receive sacral nerve stimulation. The observed success rates with both devices were low:
at 18 months following their entry into the study, 6 out of 41 (14.6%) participants in the FENIX group
and 4 out of 39 (10.3%) participants in the sacral nerve stimulation group had the device both in use
and producing a benefit. A total of 5 out of 50 (10.0%) participants allocated to receive the FENIX
device did not have a device implanted, and 15 out of 45 (33.3%) participants who did have the FENIX
device implanted needed to have it removed because of complications during the 18-month follow-up
period. A total of 21 out of 49 (42.9%) participants allocated to receive sacral nerve stimulation
did not have a permanent sacral nerve stimulation device implanted, and 0 of the 28 who did have a
permanent sacral nerve stimulation device implanted needed to have it removed during the 18-month
follow-up period. The costs associated with the FENIX device were higher because of a greater
number of participants experiencing complications, meaning that the FENIX device is unlikely to be
cost-effective in the treatment of faecal incontinence compared with sacral nerve stimulation.
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Faecal incontinence is a distressing condition that affects between 5% and 10% of the adult population.
Current treatment options include conservative measures with dietary modification and constipating
agents, pelvic floor physiotherapy with or without biofeedback therapy, and surgical intervention for
patients with moderate to severe symptoms. The most commonly used surgical intervention for patients
with faecal incontinence resistant to medical treatment is sacral nerve stimulation. Sacral nerve stimulation
involves a two-stage procedure, whereby a temporary stimulation phase is used to assess initial efficacy and
if a ≥ 50% reduction in weekly incontinence episodes or incontinence score is observed, then the patient
may proceed to a permanent sacral nerve stimulation implant. Sacral nerve stimulation is recommended by
the National Institute for Health and Care Excellence and, although short-term efficacy is reported to be
good, the long-term efficacy as reported from a decision-to-treat perspective is only around 45–50%.
Despite the high costs of the permanent implant, sacral nerve stimulation is believed to be cost-effective
compared with the only other definitive treatment for faecal incontinence: a permanent colostomy.
More recently, a new device, FENIX™ (Torax Medical, Minneapolis, MN, USA), has been introduced to
the market, consisting of a string of magnetic beads that is implanted around the anal canal to augment
the anal sphincter. Initial results from small, single-centre studies have been promising, suggesting a
≥ 50% improvement in incontinence in around 70% of participants, with a complication rate of 20% and
a device explant rate of 10%. Only one previous randomised trial has been undertaken to evaluate the
FENIX device, comparing it with the Acticon Neosphincter® (American Medical Systems, Minneapolis,
MN, USA) and showing benefits in terms of shorter operating times and length of hospitalisation, and
reduced costs.
Objectives
The objective was to undertake a randomised comparison of the safety, efficacy, and cost-effectiveness
of the FENIX device with sacral nerve stimulation for the treatment of adults with moderate to severe
faecal incontinence that is resistant to medical therapies. The primary outcome was success of the
intervention (FENIX or sacral nerve stimulation) defined as the device in use and ≥ 50% improvement
in the participant-reported Cleveland Clinic Incontinence Score at 18 months post randomisation.
The secondary outcomes included length of hospital stay, complications, reinterventions, constipation,
quality of life and cost-effectiveness.
Methods
A multicentre randomised controlled trial was undertaken across 18 NHS hospital trusts involving
colorectal surgeons who were members of the Association of Coloproctology of Great Britain and
Ireland. It was estimated that 350 participants would be required to detect at least a 20% difference
in the percentage of successes at 18 months post randomisation, where success was defined as the
device in use and ≥ 50% improvement in Cleveland Clinic Incontinence Score from baseline. Prior to
randomising participants, all surgeons had to have performed a minimum of 10 permanent sacral
nerve stimulation implants, observed a minimum of one FENIX procedure and performed two FENIX
procedures under proctorship with data captured in the registration phase of the study. For inclusion
in the study, participants had to be aged ≥ 18 years and to have been suffering from faecal incontinence
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for more than 6 months with ≥ 2 incontinent episodes per week. The aetiology of incontinence was
not specified and an anal sphincter defect of ≤ 180°, as assessed by endoanal ultrasound scan, was
allowed. Participants were randomised equally to either FENIX or sacral nerve stimulation treatment,
with minimisation factors including the treating surgeon, participant sex, severity of incontinence and
degree of anal sphincter defect. The technique for FENIX implantation was standardised according to the
manufacturer’s guidance, whereas the technique of sacral nerve stimulation was left to the surgeon’s
normal practice. Data were captured at baseline, 2 weeks post intervention and at 6, 12 and 18 months
post randomisation. The Cleveland Clinic Incontinence Score was used to assess incontinence and the
Obstructed Defaecation Score was used to assess constipation. Quality of life was assessed by participant-
reported questionnaires, using the faecal incontinence quality of life, EuroQol-5 Dimensions, five-level
version and Visual Analogue Scale, and SF-12 questionnaires. In addition, participants completed the
Health and Social Care Resource Use questionnaire.
All analyses were prespecified and conducted on an intention-to-treat basis. The results are reported
with 95% confidence intervals and p-values for fixed effects. For all end points, missing outcome data
were assumed to be missing at random, and the treatment effect was estimated via maximum
likelihood estimation using all participants with non-missing outcome data for non-longitudinal end
points. A sensitivity analysis of the primary end point was performed considering other covariates
thought to be related to participant outcome. All modelling was performed using SAS® (SAS Institute
Inc., Cary, NC, USA) version 9.4 glimmix procedure.
The economic evaluation was from the perspective of the social and health-care provider generating
cost per quality-adjusted life-year over a lifetime horizon. We analysed trial cost and quality-adjusted
life-year data and extrapolated these forward using a de novo decision-analytic model.
Results
The study was prematurely stopped in 2017 when the manufacturing company was bought by a
multinational company and the FENIX device was withdrawn from the market. Between 30 October
2014 and 23 March 2017, 322 participants were assessed for eligibility; 23 participants were registered
as training cases, and 99 participants were randomised into the study (50 FENIX and 49 sacral nerve
stimulation). The baseline characteristics of the two groups were similar and in keeping with a population
suffering from moderate to severe faecal incontinence. The median time from randomisation to FENIX
implantation was 57.0 days (range 4.0–416.0 days). The median time from randomisation to temporary
sacral nerve stimulation was 86.5 days (range 2.0–699.0 days) and the median time from randomisation
to permanent sacral nerve stimulation was 371.0 days (range 86.0–918.0). Five out of 50 participants did
not undergo FENIX implantation, and 5 out of 49 participants did not undergo temporary sacral nerve
stimulation. A total of 32 participants continued to permanent sacral nerve stimulation, of whom three
did not have a device implanted. For the primary end-point analysis, 19 participants had missing data,
meaning that there was complete data available for analysis for 80 out of 99 (80.8%) participants.
Overall, there was success for 10 out of 80 (12.5%) participants, with no statistically significant
difference between the two groups [FENIX 6/41 (14.6%) participants vs. sacral nerve stimulation
4/39 (10.3%) participants]. A longitudinal analysis using data obtained at 6, 12 and 18 months post
randomisation did not show a statistically significant difference between the treatment groups, with
no significant difference over time.
There were four intraoperative complications in four participants: three during FENIX implantation and
one during implantation of a permanent sacral nerve stimulation. A total of 42 out of 85 participants
experienced at least one postoperative complication: 33 out of 45 (73.3%) in the FENIX group and
9 out of 40 (22.5%) in the sacral nerve stimulation group. The adjusted odds ratio revealed a statistically
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significant difference between the two treatments (11.21, 95% confidence interval 2.65–47.35; p = 0.004).
A total of 15 out of 50 (30%) of the FENIX devices were explanted, usually within 6 months; there were no
explants in the sacral nerve stimulation group.
Data were available from 96 out of 99 (97%) participants for analysis of the secondary end point: the
Cleveland Clinic Incontinence Score . The results showed that having a device in use led to a statistically
significant reduction in the Cleveland Clinic Incontinence Score of 3.04 points, but with no difference
observed between the treatment groups. The quality-of-life analysis using the EuroQol-5 Dimensions,
five-level version questionnaire showed a statistically significant improvement in quality of life in
participants with the device in use (EuroQol-5 Dimensions, five-level version score 0.13 higher; p = 0.004),
with no difference between the treatment groups. This finding was not replicated in the analysis of the
Visual Analogue Scale score, with the randomised treatment producing no benefit and no difference
observed between the treatment groups over time. Analysis of faecal incontinence quality of life
showed a statistically significant improvement across all four domains when the device was in use, but
no significant difference between the treatment groups. Despite obstructed defaecation being the most
commonly reported complication following FENIX implantation, no significant difference was observed
between the treatment groups, and whether or not a participant had a device in use did not produce a
statistically significant difference in the Obstructed Defecation Score. The benefits of having a device in
use appeared to be due to improvements in physical component scores rather than mental component
scores, as assessed by the Short Form questionnaire-12 items, with no differences between the
treatment groups.
At the end of the trial period, slightly higher costs and quality-adjusted life-years (incremental = £305.50
and 0.005, respectively) were observed in the FENIX arm. The sample size available for the analysis
limits our ability to draw robust conclusions. The trial results were reversed over the lifetime horizon
(incremental = –£1306 and –0.23 for costs and quality-adjusted life-years, respectively) with sacral nerve
stimulation being the optimal option (net monetary benefit= –£3283). These analyses were relatively
robust to deterministic sensitivity analyses; however, there was significant uncertainty, with sacral nerve
stimulation having only a 55% chance of cost-effectiveness over a lifetime. Given the small sample sizes
available for parameter value generation, caution is needed in interpreting the results.
Conclusions
Interpretation of the results is limited because of the early termination of the study, which means that
the numbers available for analysis are small, with a high proportion of participants in the sacral nerve
stimulation group not undergoing permanent sacral nerve stimulation implantation or not completing the
18-month follow-up.With this caveat, the rates of success for both FENIX and sacral nerve stimulation are
disappointing and much lower than previously reported in the literature. The complication rates associated
with the FENIX device are high, with around one-third of participants undergoing explantation. For
those participants for whom a device remained in use, there were benefits in terms of improvement in
continence score and quality of life. Based on the cost-effectiveness analysis, if the FENIX device were
still available, it is uncertain whether or not it would be recommended for routine use in patients with
faecal incontinence given the costs associated with complications.
Trial registration
This trial is registered as ISRCTN16077538.
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Chapter 1 Treatment options for faecal
incontinence and rationale for SaFaRI
clinical trial
Much of the text included in this chapter has been taken from the SaFaRI protocol.1 The researchteam has previously published the protocol in the International Journal of Colorectal Disease.
Reproduced with permission from Williams et al.1 This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The text below includes minor additions and formatting
changes to the original text.
Introduction
Faecal incontinence (FI) is a distressing condition that affects between 5% and 10% of the adult
population. It is more common in female patients and with advancing age, and is the second most
common cause of admission to a nursing home. It has an impact on social, physical and mental
well-being and is a substantial burden on NHS resources.
Current treatment options
Current treatment strategies for adult FI are summarised in the National Institute for Health and Care
Excellence (NICE) 2014 guidance.2 All patients should undergo a thorough history and physical examination
to determine the nature and severity of the problem, and to identify a probable aetiological cause. Initial
management consists of a combination of patient education, dietary modification and antidiarrhoeal
medication. If this is unsuccessful, investigation in the form of endoscopic visualisation of the colorectum,
anorectal manometry (pudendal nerve testing optional), and endoanal ultrasound is performed to further
characterise the underlying disorder and inform treatment options.
Conservative therapies
Conservative therapies include pelvic floor retraining, with or without biofeedback therapy, and irrigation
techniques (rectal or antegrade irrigation). Biofeedback therapy aims to increase the patient’s awareness
of the muscles of continence and rectal sensation. Incontinent symptoms are improved in around 50% of
patients, although there appears to be a significant placebo effect, with a marked decrease in efficacy on
long-term follow-up.3 Rectal irrigation, for example using the Peristeen® system (Coloplast, Humlebæk,
Denmark), aims to clear the rectum and lower colon of faecal residue. In the short term it can have
beneficial effects, but as a long-term solution patients frequently find it unacceptably time-consuming
and inconvenient. Recently, there has been interest in the use of bulking agents to augment the anal
sphincter. Data on the efficacy of these agents is limited, but they may have a role in controlling minor
incontinence or ‘seepage’, or where an isolated sphincter defect is causing incomplete closure of the
anal canal.4
Surgical interventions
Surgical interventions are indicated for those patients with moderate to severe FI that is resistant to
the conservative therapies listed in Conservative therapies.
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Anterior sphincteroplasty, artificial bowel sphincter and dynamic graciloplasty
Anterior sphincteroplasty may be considered for patients with discrete sphincter defects, which occur
typically as a result of obstetric injury. Through a perineal incision, the disrupted sphincter muscle is
isolated and an overlapping sutured repair performed. Short-term results are reasonable, with 70%
of patients reporting an improvement in continence; however, there is a drop-off in the longer term,
with fewer than 50% of patients experiencing a benefit at 5 years.5 Patients who do worse following
anterior sphincteroplasty include those with coexistent pudendal neuropathy, multiple sphincter
defects or sphincter atrophy, and irritable bowel syndrome. Because of the poor long-term results,
there has been a move away from sphincter repair, except in well-defined cases, and an increased
enthusiasm for sacral nerve stimulation (SNS).
Another surgical intervention which may be considered to treat FI is the artificial bowel sphincter
(ABS). The ABS consists of (1) a fluid-filled silicone cuff placed around the anus, (2) a fluid-filled,
pressure-regulating balloon positioned in the abdominal wall and (3) a manual pump connecting these
components, placed in either the labia majora or the scrotum. When the cuff is inflated, the anal canal
is sealed. The fluid is transferred to the balloon by the manual pump, deflating the cuff and opening the
anal canal to allow defaecation. A successfully functioning device improves continence and quality of
life (QoL); however, it is expensive, with the device alone costing around £4000. The main problem
with the ABS is the high complication rate. Revisional surgery is needed in between 12.5% and 50% of
cases, with explantation rates between 16.7% and 41.2%.6 The majority of revisions are for cuff leaks
that are thought to arise from microperforations caused by repeated cycles of inflation and deflation
over a number of years. Most explantations are for infective complications. As a consequence, the ABS
is not in common usage.
Dynamic graciloplasty involves mobilisation of the gracilis muscle from the inner thigh and wrapping
around the anus to augment sphincter function. A neurostimulation device with an impulse generator
is implanted to adapt the type II, fast-twitch muscle fibres to type I, slow twitch, fatigue-resistant fibres.
The patient uses an external programming device to deactivate the electrical stimulation, relaxing the
muscular contraction and enabling defaecation at a voluntary time. The success rate of the operation
is between 40% and 60%.7 Like the ABS, the main problem is the high complication (infections, 28%;
device malfunction, 15%; and leg pain, 13%) and reintervention rates. The use of dynamic graciloplasty
in the UK has largely been superseded by SNS.
Sacral nerve stimulation
Sacral nerve stimulation for FI was first described in 19958 and has grown in popularity, gaining NICE
recognition as a minimally invasive treatment for moderate to severe FI. SNS works by a combination of
anal sphincter augmentation and modulation of spinal/supraspinal pathways. It benefits from a two-stage
procedure, which enables the patient to assess acceptability and the clinician to evaluate efficacy
prior to commitment to a permanent and expensive implant. An initial percutaneous nerve evaluation,
or temporary stimulation, is performed under local, regional or general anaesthetic as a day-case
procedure. A fine needle is inserted percutaneously into the sacral foramina (S3 or S4) on both sides to
determine the best response in terms of anal sphincter contraction and dorsiflexion of the great toe
(S3 stimulation). Once a satisfactory response is obtained, the temporary electrode is inserted, secured
to the skin and connected to an external test stimulator, allowing the patient to alter the stimulation
voltage. The patient is asked to keep a bowel diary for the 2–3 weeks of stimulation, which allows the
clinician to quantify the degree of response. A positive response is defined as a reduction in incontinence
episodes or incontinence score of ≥ 50% during the stimulation period.
Around 70% of patients have a good response and proceed to a permanent implant. Of these, 10%
never gain any significant improvement and 26% experience loss of efficacy, usually within the first
year.5,9–11 A further 2–5% suffer irresolvable complications and undergo explantation. Thus, from a
decision-to-treat perspective, the long-term efficacy is around 45–50%. Overall, only 50% of patients
thought to be eligible for SNS have a functioning device in the long term.
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The reasons for loss of efficacy are not clear, but may relate to device malfunction or fibrosis of the
stimulating electrode leading to loss of conduction. Pain or discomfort at the stimulator site, down the
leg or into the vagina is another commonly reported complication, experienced by 38.1% of patients.
Overall, only 58.5% of patients who have a permanent implant have a good or acceptable result in the
medium term.5
Although SNS is an effective treatment for FI, it is also very costly. The component costs alone (excluding
other direct and indirect medical costs) are £200 for the test stimulation and £9393 for the permanent
stimulator.12 A European study has calculated the 5-year cumulative costs for SNS at €22,150 per patient,
which compares with €33,996 for a colostomy and €3234 for conservative treatment.13 Despite this,
SNS has been shown to be cost-effective. The incremental cost-effectiveness ratio (ICER) for SNS is
£25,070 per quality-adjusted life-year (QALY) gained, which is within the £30,000 per QALY threshold
recommended by NICE as an effective use of NHS resources.
NICE first issued its guidance on SNS for FI in 200414 and concluded that current evidence on safety
and efficacy appeared to support its use, but that the procedure should only be performed in specialist
units by clinicians with a particular interest in the condition. A systematic review at that time included
six case series and 266 patients. In patients who had permanent implants, complete continence was
achieved in 41 to 75%, while 75 to 100% of patients experienced a decrease of ≥ 50% in the number
of incontinent episodes. Improvements were noted in both disease-specific and general QoL scores.
The most recent review, including 13 studies and 929 patients, has confirmed the short-term efficacy
of SNS.15 Although the extent of the therapeutic effect varied between studies, a significantly beneficial
effect was noted. Functional improvement was observed in 77% with idiopathic FI, 76% in sphincter
rupture/episiotomy, 78% after anal repair, and 73% after neurological injury. The benefit was not
restricted to improved continence, with several studies showing a significant improvement in QoL.9,10,13
FENIX™ continence restoration system (FENIX™ magnetic sphincter augmentation)
The FENIX™ continence restoration system, or FENIX™ magnetic sphincter augmentation (MSA)
(Torax Medical, Minneapolis, MN, USA), is a device that has been designed to reinforce the native
sphincter for the treatment of FI that is resistant to conservative therapies. It consists of a ring of
14–20 titanium beads with magnetic cores that are linked together to form a structure to be surgically
placed around the anal sphincter complex. To defecate, the patient strains in a normal way and the
force generated separates the beads to open the anal canal. Continence is restored by means of
passive attraction of the beads. Once implanted, the device does not require patient input to function.
The FENIX MSA costs £4000. Data on efficacy are limited, but they suggest a ≥ 50% improvement
in continence in 70% of patients. Complications can occur in around 20% of patients, leading to
explantation in around 10%.
Preliminary results are promising, with 70% of patients reporting a benefit; however, studies have been
small and a more rigorous evaluation is required prior to its widespread adoption.
The device is manufactured in different lengths to accommodate variations in anal canal circumference,
and has been CE (Conformité Européenne) marked since November 2011. FENIX MSA has been used
in selected European and US centres to support a feasibility trial and was first used in the NHS
in 2013.
The available evidence on safety and efficacy is limited but encouraging. Barussaud et al.16 published
data on a series of 24 patients who were implanted with FENIX between 2008 and 2012. All patients
were female, with a mean age of 64 years (range 35–78 years) and the mean duration of FI being
8.8 years (range 1–40 years). The mean follow-up was 17.6 months. There was one immediate
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postoperative complication: cardiac arrest due to drug intolerance. The patient recovered without
further sequelae. Two patients (8.7%) had the device explanted, one for device separation and one for
perineal abscess at 6 months post implant. The procedure was considered a failure for five patients
(21%) due to a lack of improvement in FI symptoms. Bowel diary results showed a significant
improvement in the number of weekly FI episodes, decreasing from 32 to 8 in a 3-week diary.
The mean Wexner score [Cleveland Clinic Incontinence Score (CCIS)] was reduced significantly from
16 points at baseline to 7 points, 8 points and 5 points at 12, 24 and 36 months, respectively. All four
domains of the faecal incontinence quality-of-life (FIQoL) questionnaire scores significantly improved
and remained stable postoperatively compared with the score at baseline.
A retrospective, case-matched comparison of the FENIX MSA with the ABS (Acticon® Neosphincter;
American Medical Systems, Minneapolis, MN, USA) in 20 patients with severe FI17 showed that
the FENIX MSA and ABS produced similar significant improvements in FI and QoL. Compared with
the ABS, the FENIX MSA was associated with a significantly shorter operating time (FENIX MSA:
62 minutes vs. ABS: 97.5 minutes; p = 0.0273) and length of hospitalisation (FENIX MSA: 4.5 days vs.
ABS: 10 days; p = 0.001). No difference was observed in postoperative complications. The ABS was
associated with more explants/revisions (FENIX MSA: 1 vs. ABS: 4; p = 0.830), a greater incidence in
postoperative constipation, and was more expensive.
Permanent stoma
For patients for whom the above surgical attempts fail to restore normal continence, the options are
limited. A permanent stoma (usually colostomy) is often the last resort for patients with intractable FI.
It is an effective strategy, but one that carries psychological and physical morbidity. Although most
patients adapt to a permanent stoma, there is a continual fear of appliance leakage that can have
an impact on social functioning. Around 50% of permanent stomas are complicated by parastomal
herniation that may require surgical intervention. Moreover, a stoma is not a cheap intervention,
with the 5-year cumulative costs estimated at £28,000.13
Rationale for the SaFaRI trial
New technologies have often been introduced into clinical practice without rigorous evaluation of
safety, efficacy and cost-effectiveness. Objective assessment has been overlooked because of the
intrinsic appeal of new innovation, the need to be a part of a ‘pioneering group’ or, worse, because of
the financial incentives from industry. Once introduced, low-grade observational evidence is often used
to keep practices going. As a result, it has often been easier to ‘stop them starting’ than to ‘start them
stopping.’18 Ideally, any new technology introduced into clinical practice should be simultaneously
evaluated, and in most cases the best way of doing this is by randomised comparison with an already
established technique. The National Institute for Health Research Horizon Scanning Centre (NIHR HSC)
was established to ‘supply timely information to key health policy and decision-makers within the NHS
about emerging health technologies that may have a significant impact on patients or the provision of health
services in the near future.’19 In May 2012, the NIHR HSC reported on the FENIX Continence Restoration
System (FENIX MSA) and concluded that ‘in order to determine its potential place in the pathway of care
for FI larger long term studies of the safety, effectiveness and cost-effectiveness of FENIX in comparison to
existing treatments are needed.’20 Therefore, although FENIX MSA may have a role to play in the treatment
of FI, the evidence was not robust enough to support its widespread adoption.
The SaFaRI trial was thus designed to undertake a rigorous, prospective assessment of the new FENIX
MSA as it was adopted into the NHS. The aim was for reliable data, collected independently from
commercial interests, to be made available on the safety and efficacy of the device. This would include
information on safety, efficacy, QoL and cost-effectiveness. Important information would be gained
on the costs associated with the device, enabling the ICER per QALY to be determined. This would
allow health-care providers to make informed decisions about value for money and future provision of
the technology.
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Sacral nerve stimulation was chosen as the comparator to FENIX MSA as SNS is currently the
preferred, and NICE-recommended,2 surgical intervention for FI that is resistant to conservative
therapies; the NIHR HSC report19 from May 2012 also identified SNS as the preferred comparator for
any randomised comparison with FENIX MSA.
Furthermore, the SaFaRI trial was designed to collect additional, important data about SNS. SNS is a
costly yet effective treatment for FI; however, concerns have been expressed about the lack of efficacy
when analysed on an intention-to-treat basis and the loss of efficacy on longer-term follow-up. The
SaFaRI study provided an additional opportunity to clarify the indications for SNS and the indicators
of success.
The opportunity also presented itself to comprehensively document, for the first time, the treatment
and associated costs for patients for whom either SNS or FENIX MSA is not successful. In effect, these
patients would provide comparative, longitudinal data of the patient pathway where FENIX MSA or
SNS is either unsuitable or unavailable.
In addition to the costs detailed above, the health economics would provide data on the short- and
long-term cost-effectiveness of FENIX MSA compared with SNS. Within the analyses, use of two
measures of health-related QoL to produce QALYs, the Short Form questionnaire-12 items (SF-12)
together with the EuroQol-5 Dimensions (EQ-5D), would allow assessment of the sensitivity of the
EuroQol-5 Dimensions, five-level version (EQ-5D-5L) to detect changes in FI, which is to date unproven.
The disease-specific questionnaire chosen to assess QoL, the FIQoL questionnaire, collects important
information on many social and psychological aspects of FI (shame, depression, enjoyment, etc.). These
aspects of FI have received little previous recognition in the literature and remain poorly defined.
Methods
Aim and objectives
The overall objectives of the study were to:
l determine the short-term safety and efficacy of FENIX MSA and SNS in adult FI
l assess FENIX MSA and SNS in terms of impact on QoL and cost-effectiveness.
Aim
The aim was to conduct a thorough evaluation of the FENIX MSA device, compared with SNS, for the
treatment of adult FI.
Primary outcome measure
The primary outcome measure was success, defined as device in use and ≥ 50% improvement in the
participant-reported CCIS at 18 months post randomisation.
Secondary outcome measures
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Trial design
SaFaRI was a prospective, UK multisite, parallel-group, randomised clinical study investigating the
safety and efficacy of the FENIX MSA for adult FI. The comparator was SNS, a preferred treatment
recommended by NICE for the treatment of FI that is resistant to conservative therapies.2 Participants
were randomised on a 1 : 1 basis to receive either FENIX MSA or SNS.
Prior to randomising participants, all participating surgeons had to have performed a minimum of
10 permanent SNS implantations, observed a minimum of one FENIX MSA procedure and performed
two FENIX MSA procedures under proctorship.
A registration phase was incorporated into the study design to enable surgeons without the required
FENIX MSA experience prior to study participation to gain the relevant experience within the scope of the
study. Within the registration phase, the first two eligible patients providing consent were registered to the
study under the training surgeon’s name and received FENIX MSA implants (there was no randomisation in
the registration phase); these two operations, which were performed under proctorship, were considered
study training cases and were not included in the main study/main trial analysis. Once the required FENIX
MSA experience had been obtained, the surgeon could progress to the randomisation phase.
The trial received national ethics approval in the UK. The trial conduct was overseen by an
independent Trial Steering Committee (TSC) and Data Monitoring and Ethics Committee (DMEC). The
trial had public and patient involvement during the trial design phase and throughout the course of the
study. The trial was registered on the International Standard Randomised Controlled Trial Number
(ISRCTN) register (16077538).
Participants
The inclusion criteria were as follows:
l aged ≥ 18 years
l able to provide written informed consent
l FI for > 6 months
l incontinent episodes of ≥ 2 per week
l suitable candidate for surgery, as judged by the operating surgeon
l suitable for either FENIX MSA or SNS (unless the patient was being registered as a training case,
in which event they only needed to be suitable for the FENIX MSA)
l anal sphincter defect < 180° as documented on endoanal ultrasound scan
l able and willing to comply with the terms of the protocol including QoL questionnaires.
The exclusion criteria were as follows:
l previous interventions for FI (i.e. SNS, FENIX MSA or ABS) (unless the patient was registered as a
training case, in which event they could have had previous interventions for FI)
l chronic gastrointestinal motility disorders causing incontinence due to diarrhoea
l obstructed defaecation, defined as an inability to satisfactorily evacuate the rectum [it was
recommended that the Obstructed Defecation Score (ODS) was calculated and was ≤ 8 for
trial inclusion]
l anal sphincter defect ≥ 180°, as documented on endoanal ultrasound scan
l an electric or metallic implant within 10 cm of anal canal
l co-existent systemic disease (e.g. scleroderma) affecting continence
l active anorectal sepsis
l diagnosis of colorectal or anal cancer within previous 2 years
l external rectal prolapse
l significant scarring of the anorectum that, as judged by the treating surgeon, would prohibit FENIX
MSA implantation or put the patient at high risk of implant erosion
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l pregnancy (it was the local surgeon’s responsibility to assess pregnancy in women of childbearing
potential)
l immunocompromised, including haematological abnormalities and treatment with steroids or other
immunomodulatory medicines
l congenital spinal abnormalities, preventing SNS implantation
l known requirement for future magnetic resonance imaging surveillance, which would be
contraindicated in the presence of metallic implant
l suspected or known allergies to titanium.
Interventions
Preoperative investigation and preparation were as per institutional protocol, which included, as
standard practice, visualisation of the colorectum (flexible sigmoidoscopy as a minimum), anorectal
manometry (pudendal nerve testing optional) and endoanal ultrasound.
Sacral nerve stimulation
Sacral nerve stimulation implantation was performed in accordance with each research site’s usual
practice. SNS implantation is a two-stage procedure. As per standard care, a temporary device was
implanted during a day-case procedure and the degree of response to the device recorded by the
participant over the course of 2 weeks. Response was assessed in accordance with each research site’s
usual practice. For the purposes of the trial, the CCIS was recorded at this time point regardless of
how the response was assessed locally.
As per routine care, if the response was positive (defined as a ≥ 50% improvement in incontinence
episodes or ≥ 50% improvement in CCIS), then a second day-case procedure was scheduled and a
permanent SNS device was implanted. If the response was negative, the temporary device was removed
and the participant did not receive any further study intervention but continued follow-up for the required
18-month period. Further treatment was as per standard practice but participants were not permitted to
undergo FENIX MSA implantation during the 18-month post-randomisation follow-up period.
Postoperative care was as per routine care, but participants had to be reviewed at clinic for trial
purposes 2 weeks postoperatively for both temporary and permanent device implants, and at 6, 12
and 18 months post randomisation as a minimum. Any further visits were according to local standard
clinical practice, but were captured on the follow-up case report forms (CRFs).
FENIX magnetic sphincter augmentation
FENIX MSA implantation was usually performed during an in-patient stay (usually of 1–3 days).
Participants for whom FENIX MSA failed were not permitted to undergo SNS during the 18-month
follow-up period. No postoperative care was required above routine wound care, but participants
had to be reviewed for trial purposes at 2 weeks postoperatively and at 6, 12 and 18 months post
randomisation as a minimum. Any further visits were performed according to local standard clinical
practice and were recorded on the follow-up CRFs.
Participant-completed questionnaires
Participants completed a number of questionnaires designed to capture FI symptoms prior to
randomisation (baseline), at 2 weeks post operation and at 6, 12 and 18 months post randomisation:
l The CCIS.21 The CCIS assesses five parameters associated with incontinence – incontinence to solid,
incontinence to liquid, incontinence to gas, use of pads, and lifestyle restriction. Each parameter is
scored 0–4, with ‘0’ for never and ‘4’ for every day. The five parameters are added to give a total
score out of 20.
l The ODS.22 The ODS consists of five items: excessive straining, incomplete rectal evacuation, use of
enemas and/or laxatives, vaginal-anal-perineal digitations, and abdominal discomfort and/or pain. Each
item is graded from 0 to 4 with a score ranging from 0 (no symptoms) to 20 (very severe symptoms).
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l The FIQoL questionnaire.23 This questionnaire is composed of 29 items that make up four scales:
lifestyle (10 items), coping/behaviour (9 items), depression/self-perception (7 items) and
embarrassment (3 items). Scoring is derived from a participant-completed questionnaire that
assesses the impact of FI on four domains of QoL. Scales range from 1 to 5, with 1 indicating a
lower functional QoL. Scale scores are derived by averaging the response to all items in the scale.
l Health and Social Care Resource Use. The questionnaire is composed of questions related to
contact with primary, community and social care services. The questionnaire consists primarily of
‘tick-box’ completion questions.
l SF-12.24 The SF-12 is a 12-item subset of the Short Form questionnaire-36 items version 2 that
measures the same eight domains of health. It is a brief, reliable measure of overall health status.
It is useful in large population health surveys and has been used extensively as a screening tool.
l EQ-5D-5L.25 This is a well-validated questionnaire used to assess generic QoL; it provides a simple
descriptive profile and a single index value for health status.
Participants completed all of the above listed questionnaires at baseline and at 6, 12 and 18 months
post randomisation. In addition to these time points, participants completed the CCIS and the Health
and Social Care Resource Use questionnaire at 2 weeks postoperatively (for temporary SNS and FENIX
MSA only). For the permanent SNS, participants completed the Health and Social Care Resource Use
questionnaire at 2 weeks postoperatively.
Summary of protocol changes
A summary of all substantial amendments to the SaFaRI protocol can be found in Table 1.
Early trial closure
On 23 March 2017, the SaFaRI trial team received formal notice from Torax Medical (the manufacturer
of the FENIX MSA device) that the decision had been made to suspend the commercial sale of the FENIX
MSA device in the UK and other European countries for ‘strategic and business reasons’. As a result
of this, recruitment into the SaFaRI trial, regrettably, had to cease with immediate effect.
Following the withdrawal of the FENIXMSA device and with approval from the Research Ethics Committee,
all patients who had consented for the trial up to 23March 2017, and had been randomised to the FENIX
MSA arm but had not yet had surgery, were given the chance to have the FENIXMSA device implanted if
they still wished to proceed with the operation as randomised. Any patients not wishing to undergo a FENIX
MSA implantation, in the light of the fact that the device had been withdrawn, were offered alternative FI
treatment as per local standard practice (this included the option of undergoing the alternative study
intervention, SNS).
In total, 99 participants were randomised into the SaFaRI trial and 23 participants were registered as
FENIX MSA training cases. A consequence of recruiting only 99 patients out of the target sample size
of 350 is that the study is substantially underpowered to detect differences between the treatment
arms, in particular with respect to the primary end point. Although the recruitment total was
significantly less than the originally planned sample size of 350 participants, it was felt that continuing
to follow up all randomised participants until the end of the planned follow-up period (i.e. 18 months
post randomisation) would still provide valuable data that, at the very least, could provide some initial
evidence; at the time of trial closure, SaFaRI was also the largest randomised trial of SNS to date.
The National Institute for Health Research was amenable to the trial team’s proposal to continue with
the planned follow-up period, and, as a result, all patients who had been randomised into the SaFaRI
trial continued to be followed up until 18 months post randomisation. The last participant’s final
follow-up took place in September 2018.
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TABLE 1 Summary of protocol changes
Version and date Summary of changes
V1.0, 9 April 2014 N/A: original protocol submitted for ethics review
V2.0, 10 October 2014 l Update to contacts
l Clarification of primary end point/outcome: ‘in situ’ amended to ‘in use’
l Text regarding FENIX MSA device supply arrangements revised
l Update to data being collected (confirmation that device is both ‘in situ’ and ‘in use’)
l Deaths to be reported up to 18 months post randomisation rather than 18 months
after the last participant is randomised
l CTRU responsibilities for safety reporting to the REC: serious complications
removed
l Study summary and GP letter for the Bladder and Bowel Foundation website
l Addition of text to explain that a thank-you letter will be sent on receipt of a
completed QoL questionnaire, or, if not received, a reminder letter will be sent
l Inclusion of cover, reminder and thank-you letters for the postal QoL
questionnaires that are being sent to participants from CTRU at 6, 12 and
18 months post randomisation
V3.0, 30 April 2015 l Inclusion of Scottish sites in the trial
l A new consent form was drafted, for participants recruited in Scotland only, to
include advance consent to continue to collect follow-up and safety data should
capacity be lost during the course of the trial
l Process for Scottish participants detailed in a new paragraph in the protocol
l The provision to obtain assent from personal or nominated consultees remained;
however, these sections were applicable only to participants recruited in England
and relevant sections in the protocol were highlighted as such
l Clarification to inclusion criterion 6: if the patient is being registered as a training
case, they only need to be suitable for the FENIX MSA
l Clarification to exclusion criterion 1: if the patient is being registered as a training
case, they can have had previous interventions for FI
V4.0, 7 March 2016 l Removal of option for participants to complete the baseline and 2-week
postoperative QoL packs (temporary SNS, permanent SNS and FENIX MSA) at
home and enforce that these questionnaires are completed in clinic only. Wording
on the baseline and 2-week postoperative QoL pack coversheets and in the
protocol amended to reflect this change
l Introduction of a questionnaire guidance sheet to assist with participant-reported
CCIS questionnaire completion in clinic at baseline and 2 weeks postoperatively
l Clinical CCIS to be collected at all follow-up time points to guard against attrition
of the primary end point due to non-completion of the patient-reported outcome.
CCIS collected in clinic to be incorporated into methods used to impute missing
participant-reported CCIS
l Wording in protocol amended to ensure that it is clear that the primary end point
would be based on the participant-reported CCIS (and not the clinical score)
l Date of completion, specifically for the CCIS, added to the participant-completed
QoL questionnaires at all follow-up time points as this fed directly into the primary
end point and thus would allow for a more robust primary analysis
l Clarification that the 6-month follow-up assessment could be conducted via
telephone if the participant was unable to attend the clinic in person
l Removal of the word ‘endoscopic’ before visualisation of colorectum with regard
to the preoperative investigations as it had been clinically confirmed that the
visualisation of the colorectum did not need to be carried out endoscopically
l A semantic alteration to clarify that the primary end point is the ‘success’ of each
device, and not the ‘difference in the percentage of successes [. . .] between the
two treatments’
l Recommendation that the ODS is calculated and is no more than 8 for inclusion in
the trial added for guidance
l Minor administrative changes throughout the protocol
V4.0, 7 March 2016 No change to protocol. Substantial amendment submitted to formally notify the REC
of the early trial closure owing to the withdrawal from the market of the FENIX
MSA device
CTRU, Clinical Trials Research Unit; GP, general practitioner; N/A, not applicable; REC, Research Ethics Committee.
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The primary end point was success, defined as device in use and ≥ 50% improvement (between the
baseline and 18-month scores) in the participant-reported CCIS, at 18 months post randomisation.
Secondary end points
Secondary end points included:
l the safety of FENIX MSA or SNS, as judged by explant rates, operative (this included those occurring
during theatre time and post-surgery hospital stay) and postoperative (up to and including 12 months
from the date of the last study surgery) complications
l change from baseline in generic and disease-specific QoL as measured by CCIS, ODS, FIQoL,
EQ-5D-5L and SF-12 at 6, 12 and 18 months post randomisation
l cost-effectiveness
l success at 6 and 12 months as defined in the primary end point.
Sample size
A total of 350 participants were required to detect at least a 20% difference in the percentage of
successes at 18 months post randomisation (where success was defined as device in use and ≥ 50%
CCIS improvement from baseline) between FENIX MSA and SNS at a 5% level of significance, with
90% power, assuming approximately 40% success in the SNS arm and allowing for 20% loss to follow-up.
However, the number of patients recruited was 99.
Randomisation
Following confirmation of written informed consent and eligibility, patients were randomised into the
trial by authorised members of staff at the trial sites. Randomisation was performed centrally using the
Clinical Trials Research Unit (CTRU) automated 24-hour telephone randomisation system. Authorisation
codes and personal identification numbers (PINs), provided by the CTRU, were required to access the
randomisation system.
Participants were randomised on a 1 : 1 basis to receive either FENIX MSA or SNS, and were allocated
a unique study number. A computer-generated minimisation programme that incorporated a random
element was used with the following minimisation factors:
l treating surgeon
l participant sex (male or female)
l severity of incontinence (CCIS)
¢ mild to moderate: CCIS ≤ 10 points
¢ moderate to severe: CCIS > 10 points.
l degree of anal sphincter defect on endoanal ultrasound
¢ no anal sphincter defect
¢ anal sphincter defect ≤ 90°
¢ > 90° anal sphincter defect < 180°.
Blinding
The study was not blinded to participants, medical staff or clinical trial staff because of the difference
between the two devices being compared (SNS treatment requires a temporary implant followed by a
permanent implant if successful and involves patient input to function).
TREATMENT OPTIONS FOR FAECAL INCONTINENCE AND RATIONALE FOR SAFARI CLINICAL TRIAL
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Statistical methods
Unless otherwise stated, all analyses were prespecified and conducted on the intention-to-treat
population (i.e. all randomised participants were categorised into treatment groups based on their
randomisation regardless of what treatment they subsequently received). All hypothesis tests were
two-sided and conducted at the 5% level of significance. Estimates and their corresponding 95%
confidence intervals (CIs) and p-values are presented for fixed effects. For all end points, missing
outcome data were assumed to be missing at random, and the treatment effect was therefore
estimated via maximum likelihood estimation using all participants with non-missing outcome data for
non-longitudinal end points (this is referred to as a complete case analysis for the remainder of the
report). All models were fitted using SAS® v9.4 (SAS Institute Inc., Cary, NC, USA). (SAS and all other
SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute
Inc. in the USA and other countries. ® indicates USA registration.)
Primary end point: device in use and ≥ 50% improvement in CCIS at 18 months
post randomisation
The primary analysis was a complete case analysis. Multilevel logistic regression was used to estimate
the odds ratios between treatment groups for a ‘success’ in terms of the primary end point, adjusting
for all minimisation factors. All minimisation factors were included as fixed effects, except randomising
surgeon, which was included as a random effect. A random intercept model was fitted using maximum
likelihood via adaptive quadrature, and all modelling was performed using the SAS v9.4 glimmix procedure.
A sensitivity analysis was performed to consider additional covariates in the primary analysis
regression model that were thought to be related to patient outcome. These covariates were:
l age (years)
l body mass index (BMI)
l American Society of Anesthesiologists (ASA) grade
l aetiology of incontinence (obstetric trauma, idiopathic, iatrogenic, neurological conditions)
l type of incontinence (urge predominant, passive predominant, mixed urge and passive)
l ODS
l FI medication.
Secondary end point: device in use and ≥ 50% improvement in CCIS at 6 months or
12 months post randomisation
Success at 6 or 12 months was analysed using a multilevel logistic regression model, adjusting for all
of the minimisation factors, to estimate the odds ratios. All minimisation factors were included as fixed
effects, except randomising surgeon, which was included as a random effect.
Secondary end point: intraoperative complications
Intraoperative complications were modelled using a multilevel logistic model to estimate the odds ratio
between the treatment groups for whether or not participants had an intraoperative complication,
adjusting for all minimisation factors. All minimisation factors were included as fixed effects, except
randomising surgeon, which was included as a random effect with a random intercept.
Secondary end point: postoperative complications and reinterventions
Postoperative complications were modelled using a multilevel logistic model to estimate the odds ratio
between the treatment groups for whether participants had a postoperative complication or not,
adjusting for all minimisation factors. All minimisation factors were included as fixed effects, except
randomising surgeon, which was included as a random effect with a random intercept and slope.
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Secondary end point: device explants
The number of explants was analysed using a multilevel logistic regression model, adjusting for all of
the minimisation factors, to estimate the odds ratios. All minimisation factors were included as fixed
effects, except randomising surgeon, which was included as a random effect.
Quality-of-life end points
All QoL end points were modelled using a three-level multilevel model to account for the hierarchical
nature of the repeated measures data and also for the clustering effect of the operating surgeon. All
models were adjusted for the minimisation factors, with the minimisation factors included as fixed
effects, except for the randomising surgeon, which was included as a random intercept.
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Between 30 October 2014 and 23 March 2017, 322 patients were assessed for eligibility across
18 sites. Ninety-nine of these patients were randomised into the SaFaRI study and 23 participants were
registered as FENIX MSA training cases. Recruitment by site can be seen in Table 2. A Consolidated
Standards of Reporting Trials (CONSORT) flow diagram showing all patients screened for eligibility can
be seen in Figure 1.
Baseline data
The minimisation factors are summarised by treatment arm across all randomised patients in Table 3.
Summaries of additional baseline characteristics are given in Table 4. All the minimisation factors and
baseline characteristics are well balanced between the two treatment arms.
TABLE 2 Recruitment by site
Site number Site name Randomised patients, n Registered patients, n
00050 St James’s University Hospital 45 1
00170 University Hospital of North Durham 4 1
00114 Southampton General Hospital 2 0
00232 The Northern General Hospital 14 0
00052 St Peter’s Hospital 5 0
00108 Poole Hospital 7 2
00002 Royal Devon and Exeter Hospital 3 0
00153 The Churchill Hospital 0 3
00172 Wythenshawe Hospital 4 0
00099 Good Hope Hospital 2 3
10908 University College London Hospital 0 2
00080 Manchester Royal Infirmary 4 0
00117 Bristol Royal Infirmary 4 2
00072 Royal Victoria Infirmary 2 2
00023 Dewsbury District Hospital 1 2
00317 St Mark’s Hospital 1 2
00031 Leicester Royal Infirmary 1 2
00118 Derriford Hospital 0 1
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The time from randomisation to surgery can be seen in Figure 2. The time to implant of the permanent
device was very different between the two treatment arms, with some SNS participants not receiving a
permanent device until more than 18 months post randomisation. The reason for the delays in the SNS











• Missing CCIS, n = 9
Analysed
(n = 39)
• Missing CCIS, n = 10
Allocated to FENIX MSA
(n = 50)
• Received allocated intervention, n = 45
• Did not receive allocated intervention, n = 5
    • Patient no longer wanted surgery, n = 2
    • Withdrawn for not attending
        appointments, n = 1
    • Withdrawn due to diagnosis of MND, n = 1
    • Withdrawn as required sigmoid
        colectomy, n = 1
Excluded
(n = 223)
• Did not meet inclusion criteria, n = 126
• Declined to participate, n = 57
• Too ill to consent, n = 2
• Other, n = 36
• Reason not given, n = 2
Allocated to SNS
(n = 49)
• Received allocated intervention, n = 44
• Did not receive allocated intervention, n = 5
    • Withdrawn for not attending/declining 
        theatre dates, n = 1
    • Patient no longer wanted surgery, n = 3
    • Awaiting results for another health issue,
        n = 1
Discontinued intervention
(n = 15)
• Lack of response to temporary SNS, n = 13
• Patient did not want further surgery, n = 1
• Patient did not have device implanted, n = 1
FIGURE 1 The CONSORT flow diagram. MND, motor neuron disease.
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Primary end point: device in use and ≥ 50% improvement in Cleveland
Clinic Incontinence Score at 18 months post randomisation
A total of 80 out of 99 (80.8%) participants were included in the primary analysis as 19 participants
had missing primary outcome data. The pathway for participants in the primary analysis can be seen
in Figure 3.
TABLE 3 Minimisation factors
Stratification factor FENIX MSA, n (%) SNS, n (%) Total, n (%)
Surgeon ID
2 10 (20.0) 12 (24.5) 22 (22.2)
1 11 (22.0) 8 (16.3) 19 (19.2)
3 6 (12.0) 8 (16.3) 14 (14.1)
31 3 (6.0) 4 (8.2) 7 (7.1)
26 2 (4.0) 3 (6.1) 5 (5.1)
4 3 (6.0) 1 (2.0) 4 (4.0)
12 3 (6.0) 1 (2.0) 4 (4.0)
21 2 (4.0) 2 (4.1) 4 (4.0)
30 2 (4.0) 2 (4.1) 4 (4.0)
36 1 (2.0) 3 (6.1) 4 (4.0)
32 2 (4.0) 1 (2.0) 3 (3.0)
8 1 (2.0) 1 (2.0) 2 (2.0)
15 1 (2.0) 1 (2.0) 2 (2.0)
25 1 (2.0) 1 (2.0) 2 (2.0)
5 0 (0.0) 1 (2.0) 1 (1.0)
23 1 (2.0) 0 (0.0) 1 (1.0)
999 1 (2.0) 0 (0.0) 1 (1.0)
Total 50 (100) 49 (100) 99 (100)
Sex
Female 49 (98.0) 47 (95.9) 96 (97.0)
Male 1 (2.0) 2 (4.1) 3 (3.0)
Total 50 (100) 49 (100) 99 (100)
CCIS
≤ 10 points (mild to moderate) 6 (12.0) 5 (10.2) 11 (11.1)
> 10 points (moderate to severe) 44 (88.0) 44 (89.8) 88 (88.9)
Total 50 (100) 49 (100) 99 (100)
Anal sphincter defect
No anal sphincter defect 27 (54.0) 27 (55.1) 54 (54.5)
≤ 90° 19 (38.0) 18 (36.7) 37 (37.4)
> 90° to < 180° 4 (8.0) 4 (8.2) 8 (8.1)
Total 50 (100) 49 (100) 99 (100)
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TABLE 4 Baseline characteristics
Characteristic FENIX MSA SNS Total
Age (years)
Mean (SD) 60.6 (13.1) 60.8 (14.3) 60.7 (13.7)
Median (range) 61.5 (30.0–82.0) 59.0 (35.0–90.0) 59.0 (30.0–90.0)
IQR 50.0–71.0 52.0–72.0 52.0–71.0
Missing 0 0 0
n 50 49 99
Ethnicity, n (%)
White 47 (94.0) 49 (100.0) 96 (97.0)
Mixed 1 (2.0) 0 (0.0) 1 (1.0)
Asian (Indian) 1 (2.0) 0 (0.0) 1 (1.0)
Black 1 (2.0) 0 (0.0) 1 (1.0)
Total 50 (100) 49 (100) 99 (100)
Incontinence type, n (%)
Mixed urge and passive 16 (32.0) 20 (40.8) 36 (36.4)
Urge predominant 13 (26.0) 12 (24.5) 25 (25.3)
Passive predominant 8 (16.0) 4 (8.2) 12 (12.1)
Missing 13 (26.0) 13 (26.5) 26 (26.3)
Total 50 (100) 49 (100) 99 (100)
FI aetiology, n (%)
Obstetric trauma 29 (58.0) 26 (53.1) 55 (55.6)
Idiopathic 11 (22.0) 15 (30.6) 26 (26.3)
Iatrogenic 5 (10.0) 1 (2.0) 6 (6.1)
Neurological conditions 1 (2.0) 1 (2.0) 2 (2.0)
Other 4 (8.0) 6 (12.2) 10 (10.1)
Total 50 (100) 49 (100) 99 (100)
ASA grade, n (%)
1 25 (50.0) 23 (46.9) 48 (48.5)
2 24 (48.0) 21 (42.9) 45 (45.5)
3 1 (2.0) 5 (10.2) 6 (6.1)
Total 50 (100) 49 (100) 99 (100)
Length of time suffered FI (months)
Mean (SD) 71.6 (64.6) 89.9 (90.8) 80.6 (78.6)
Median (range) 60.0 (9.0–384) 60.0 (12.0–480) 60.0 (9.0–480)
IQR 36.0–84.0 27.0–114 36.0–96.0
Missing 0 1 1
n 50 48 98
Average number of episodes per week
Mean (SD) 7.4 (6.95) 7.0 (7.01) 7.2 (6.94)
Median (range) 5.0 (2.0–28.0) 4.0 (1.5–30.0) 4.3 (1.5–30.0)
IQR 3.0–7.0 2.0–10.0 2.5–8.0
Missing 1 0 1
n 49 49 98
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TABLE 4 Baseline characteristics (continued )
Characteristic FENIX MSA SNS Total
Resting pressure (cmH20)
Mean (SD) 52.4 (28.2) 58.4 (29.2) 55.4 (28.7)
Median (range) 48.0 (10.0–120) 53.0 (19.0–133) 51.5 (10.0–133)
IQR 33.0–73.0 35.0–77.5 34.0–75.0
Missing 0 1 1
n 50 48 98
Squeeze pressure (cmH20)
Mean (SD) 77.0 (50.0) 84.8 (42.0) 80.8 (46.2)
Median (range) 69.5 (7.0–269) 85.5 (22.0–199) 71.0 (7.0–269)
IQR 44.0–105 49.0–116 46.0–109
Missing 0 1 1
n 50 48 98
Threshold volume (ml)
Mean (SD) 57.6 (35.0) 53.1 (39.3) 55.5 (36.9)
Median (range) 52.0 (14.0–180) 46.0 (10.0–200) 47.0 (10.0–200)
IQR 32.5–79.0 30.0–60.0 30.0–74.0
Missing 10 15 25
n 40 34 74
Maximum tolerated volume (ml)
Mean (SD) 127 (60.6) 137 (69.1) 131 (64.4)
Median (range) 112 (35.0–270) 117 (37.0–292) 114 (35.0–292)
IQR 85.0–160 77.0–195 80.0–180
Missing 10 15 25
n 40 34 74
Internal anal sphincter defect, n (%)
Yes 8 (16.0) 10 (20.4) 18 (18.2)
No 41 (82.0) 39 (79.6) 80 (80.8)
Missing 1 (2.0) 0 (0.0) 1 (1.0)
Total 50 (100) 49 (100) 99 (100)
External anal sphincter defect, n (%)
Yes 20 (40.0) 19 (38.8) 39 (39.4)
No 29 (58.0) 30 (61.2) 59 (59.6)
Missing 1 (2.0) 0 (0.0) 1 (1.0)
Total 50 (100) 49 (100) 99 (100)
ODS
Mean (SD) 7.4 (3.78) 7.1 (3.62) 7.3 (3.68)
Median (range) 7.0 (2.0–18.0) 8.0 (2.0–17.0) 7.0 (2.0–18.0)
Missing 5 6 11
n 45 43 88
continued
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TABLE 4 Baseline characteristics (continued )
Characteristic FENIX MSA SNS Total
BMI (kg/m2)
Mean (SD) 28.8 (5.59) 28.9 (5.78) 28.9 (5.65)
Median (range) 28.8 (19.1–53.0) 28.7 (19.2–45.0) 28.7 (19.1–53.0)
Missing 1 0 1
n 49 49 98
CCIS (points)
Mean (SD) 14.4 (3.15) 14.7 (2.95) 14.6 (3.04)
Median (range) 14.5 (6.0–20.0) 15.0 (9.0–20.0) 15.0 (6.0–20.0)
Missing 4 3 7
n 46 46 92





















































FIGURE 2 Time from randomisation to surgery. a, Patients that received operation after 18 months’ follow-up have
length of follow-up set to 0. SD, standard deviation.
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The characteristics for participants included in the primary analysis are presented in Table 5.
The primary end point was not evaluable for 19 out of 99 randomised patients: 9 out of 50 patients
randomised to FENIX MSA and 10 out of 49 patients randomised to SNS (see Figure 3). For the
remaining 80 out of 99 patients with an evaluable primary end point, the rate of ‘success’ was 10 out
of 80 (12.5%) patients overall: 6 out of 41 (14.6%) patients in the FENIX MSA arm and 4 out of 39 (10.3%)
patients in the SNS arm (Table 6). The unadjusted odds ratio was 1.50 (95% CI 0.39 to 5.78; p = 0.56).
Summaries of the two individual components of the primary end point have been provided in
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FIGURE 3 Diagram of participants in primary analysis. a, Due to other health issues; b, due to complication during procedure.
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TABLE 5 Characteristics for participants included in primary analysis
Variable FENIX MSA SNS Total
CCIS at baseline (points)
Mean (SD) 14.2 (3.23) 14.6 (3.05) 14.4 (3.13)
Median (range) 14.0 (6.0–20.0) 14.5 (9.0–20.0) 14.0 (6.0–20.0)
Missing, n 2 1 3
n 39 38 77
CCIS at 18 months (points)
Mean (SD) 11.3 (4.42) 12.0 (4.57) 11.7 (4.48)
Median (range) 11.5 (3.0–17.0) 12.0 (1.0–19.0) 12.0 (1.0–19.0)
Missing, n 13 6 19
n 28 33 61
Sex, n (%)
Male 1 (2.4) 2 (5.1) 3 (3.8)
Female 40 (97.6) 37 (94.9) 77 (96.3)
Total 41 (100) 39 (100) 80 (100)
CCIS stratification factor, n (%)
≤ 10 points (mild to moderate) 6 (14.6) 5 (12.8) 11 (13.8)
> 10 points (moderate to severe) 35 (85.4) 34 (87.2) 69 (86.3)
Total 41 (100) 39 (100) 80 (100)
Anal sphincter defect, n (%)
No anal sphincter defect 22 (53.7) 22 (56.4) 44 (55.0)
≤ 90° 16 (39.0) 13 (33.3) 29 (36.3)
> 90° to < 180° 3 (7.3) 4 (10.3) 7 (8.8)
Total 41 (100) 39 (100) 80 (100)
Randomising surgeon, n (%)
1 10 (24.4) 6 (15.4) 16 (20.0)
2 10 (24.4) 10 (25.6) 20 (25.0)
3 5 (12.2) 6 (15.4) 11 (13.8)
4 3 (7.3) 1 (2.6) 4 (5.0)
5 0 (0.0) 1 (2.6) 1 (1.3)
8 0 (0.0) 1 (2.6) 1 (1.3)
12 2 (4.9) 1 (2.6) 3 (3.8)
15 1 (2.4) 1 (2.6) 2 (2.5)
21 2 (4.9) 2 (5.1) 4 (5.0)
23 1 (2.4) 0 (0.0) 1 (1.3)
25 0 (0.0) 1 (2.6) 1 (1.3)
26 1 (2.4) 2 (5.1) 3 (3.8)
30 0 (0.0) 1 (2.6) 1 (1.3)
31 3 (7.3) 2 (5.1) 5 (6.3)
32 2 (4.9) 1 (2.6) 3 (3.8)
Other 1 (2.4) 3 (7.7) 4 (5.0)
Total 41 (100) 39 (100) 80 (100)
SD, standard deviation.
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The odds ratio adjusting for the minimisation factors was 1.45 (95% CI 0.36 to 5.83; p = 0.59).
The adjusted estimates of odds ratios and 95% CIs are presented in Table 7. The model shows no
statistically significant differences between any of the minimisation factors, although this would be
expected owing to the small number of patients recruited, which has led to large standard errors (SEs)
of the estimates (i.e. wide CIs and underpowered hypothesis tests).
The estimated random effects with respect to surgeons were equal to 0. The SE was not estimable
owing to the low numbers of patients operated on by each surgeon (see Table 5).
In Appendix 1, Figure 30 shows the empirical probability plot for the primary analysis model, which can be
used to compare actual Pearson residuals with expected Pearson residuals. The y-axis is the actual Pearson
residual value, the x-axis is the empirical median Pearson residual expected under our fitted model
assumptions. Each dot represents the actual Pearson residual for an individual patient. If the model fitted
perfectly, we would expect all of the dots to lie on the reference line. The band in Appendix 1, Figure 30,
represents the interval between the empirical 2.5th percentile and 97.5th percentile empirical Pearson
residual. There are some areas where the reference line is outside the band, meaning that the model may
not fit the data too well, but this is due to the small sample size and the rarity of successful outcomes.
In Appendix 1, Figure 31 presents the plot of exponentiated delta-betas (y-axis) versus patient identifier.
Exponentiated delta-betas further from 1 indicate greater influence of the observation on the estimated
treatment effect. Patients with a success for the primary end point are more influential than patients
without success for the primary end point, which may be expected given that success was an uncommon
occurrence. There does not appear to be any other observations with a large influence on the model.
Sensitivity analysis: additional covariates
Owing to the small number of ‘successes’, performing the sensitivity analysis with additional covariates
that was described in the analysis plan was inappropriate.
TABLE 6 Number of successes at 18 months post randomisation
Success FENIX MSA SNS Total
18 months post randomisation, n (%)
Unsuccessful 35 (85.4) 35 (89.7) 70 (87.5)
Successful 6 (14.6) 4 (10.3) 10 (12.5)
Total 41 (100) 39 (100) 80 (100)
TABLE 7 Fixed effects of primary end point model
Effect Odds ratio Odds ratio 95% CI p-value
FENIX MSA (vs. SNS) 1.453 0.362 to 5.827 0.5926
Male (vs. female) < 0.001 < 0.001 to infinity 0.9957
Baseline CCIS > 10 points (vs. baseline CCIS
≤ 10 points)
0.631 0.110 to 3.614 0.5993
Anal sphincter defect ≤ 90° (vs. no defect) 1.108 0.260 to 4.723 0.8883
Anal sphincter defect > 90° to < 180° (vs. no defect) 1.238 0.115 to 13.298 0.8579
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Longitudinal analysis
As the primary end point was measured at 6, 12 and 18 months post randomisation, a longitudinal
analysis using the data at each time point was performed. The model did not adjust for the stratification
factors because of the added complexity and the number of missing data. In addition, the stratification
factors caused the model to fail to converge.
The fixed effects of the model can be seen in Table 8. The estimated random effect caused by the
operating surgeon was 1.52 (SE 0.99) and the estimated random effect caused by within patient
measurements was 1.19. The model does not show a significant difference between the treatment
arms (p = 0.20) or in change over time (p = 0.17), although, again, it is worth noting that the estimates
have large SEs due to the small sample size.
The model results can be seen in Figure 4.
Secondary end point: device in use and ≥ 50% improvement in Cleveland
Clinic Incontinence Score at 12 months post randomisation
Success at 12 months post randomisation was evaluable for 67 out of 99 (67.7%) participants. Thirteen
patients (1 FENIX and 12 SNS) were not included in this analysis as they had not had a permanent
device fitted within 12 months of randomisation because of surgical capacity in the trial sites. The
other 19 patients were not included because of missing CCIS at baseline, at 12 months post randomisation,





























FIGURE 4 Longitudinal model results.
TABLE 8 Fixed effects of longitudinal model
Effect Estimate Estimate 95% CI p-value
FENIX MSA (vs. SNS) 1.429 0.281 to 7.261 0.20
Time (months) 1.039 0.914 to 1.180 0.17
Time and treatment interaction 1.278 0.902 to 1.812 0.27
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A total of 4 out of 27 (14.8%) patients did not have a temporary SNS device fitted (and therefore did not
have a permanent device implanted) because they withdrew from surgery before the temporary SNS
operation. A total of 4 out of 40 (10%) patients in the FENIX arm did not have a FENIX device implanted
as a result of withdrawing from surgery. Seventeen out of 27 (63%) patients did not have a permanent
SNS device implanted because of either withdrawal (n = 5) or the lack of success of the temporary device
(n = 12). Ten out of 40 (25%) patients who were randomised to FENIX had the device explanted; there
were no explants in the SNS arm. The number of successes is summarised in Table 9. Owing to the small
number of successes at 12 months, the models fitted were not meaningful and so are not presented.
Secondary end point: device in use and ≥ 50% improvement in Cleveland
Clinic Incontinence Score at 6 months post randomisation
Success at 6 months post randomisation was evaluable for 56 out of 99 (56.6%) patients. Twenty-three
patients (3 FENIX and 20 SNS) were not included in this analysis because they had not had a
permanent device fitted within 6 months of randomisation owing to surgical capacity at trial sites.
The other 20 patients were not included because of missing CCIS at baseline, 6 months post randomisation,
or at both time points.
A total of 3 out of 18 (16.7%) patients did not have a temporary SNS device implanted (and therefore
no permanent SNS device was implanted) because of withdrawal from surgery. Two out of 38 (5.3%)
of patients randomised to FENIX did not have a permanent device implanted because of withdrawal
from surgery. Thirteen out of 18 (72.2%) patients did not have a permanent device fitted because of
withdrawal (n = 4) or the lack of efficacy of the temporary SNS device (n = 9). Nine patients in the
FENIX arm (76.3%) had the device explanted within 6 months of randomisation and there were no
explants in the SNS arm. The number of successes in each arm is summarised in Table 10. Owing to the
small number of successes at 6 months, the models fitted did not converge and so are not presented.
TABLE 10 Number of successes at 6 months post randomisation
Success FENIX MSA SNS Total
6 months post randomisation, n (%)
Unsuccessful 33 (86.8) 18 (100.0) 51 (91.1)
Successful 5 (13.2) 0 (0.0) 5 (8.9)
Total 38 (100) 18 (100) 56 (100)
TABLE 9 Number of successes at 12 months post randomisation
Success FENIX MSA SNS Total
12 months post randomisation, n (%)
Unsuccessful 35 (87.5) 26 (96.3) 61 (91.0)
Successful 5 (12.5) 1 (3.7) 6 (9.0)
Total 40 (100) 27 (100) 67 (100)
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Secondary end point: intraoperative complications
In total, 89 out of 99 patients (89.9%) had intraoperative complication data; 45 patients received an
operation in the FENIX arm and 44 patients received an operation in the SNS arm.
There were four intraoperative complications in four patients; 3 out of 45 patients (6.7%) who were
randomised to FENIX and received the operation had an intraoperative complication, and 1 out
of 44 patients (2.3%) who were randomised to SNS and received at least one operation had an
intraoperative complication, giving an overall complication rate of 4.5% (4/89) in randomised patients.
The complication in the SNS arm was an unexpected serious complication (USC). The details are as follows:
l USC – anaphylaxis
l Clavien–Dindo grade – IVb
l USC description – patient became tachycardic, hypotensive and flushed following administration of
Teicoplanin (Targocid, Sanofi, Paris, France) prior to their anaesthetic for insertion of SNS
l Outcome – recovered.
There were three intraoperative complications in the FENIX arm, none of which was serious.
The complications were bleeding, cyst found in recto vaginal septum, and rectal perforation.
Secondary end point: postoperative complications
A total of 85 out of 99 patients (85.9%) were included in the analysis of postoperative complications;
10 patients were not included due to not receiving an operation and four patients were not included
due to missing follow-up forms. There were 42 out of 85 (49.4%) patients who experienced at least
one postoperative complication: 33 out of 45 patients (73.3%) in the FENIX MSA arm and 9 out of
40 patients (22.5%) in the SNS arm (Table 11). The unadjusted odds ratio of having a complication in
the FENIX MSA arm was 7.77 (95% CI 3.0 to 20.0; p< 0.001).
Figure 2 shows the time from randomisation to operation and Table 12 shows the time from randomisation
to first complication. Complications data were collected at 6, 12 and 18 months’ post-randomisation
TABLE 12 Time from operation to first complication
Parameter FENIX MSA SNS Total
Mean (SD) (days) 80.0 (148.72) 79.3 (123.87) 79.8 (142.33)
Median (range) (days) 12.0 (0.0–540.0) 15.0 (0.0–355.0) 13.0 (0.0–540.0)
Participants, n 33 9 42
SD, standard deviation.
TABLE 11 Number of patients experiencing at least one postoperative complication
Did patient experience a postoperative
complication?, n (%) FENIX MSA SNS Total
Yes 33 (73.3) 9 (22.5) 42 (49.4)
No 12 (26.7) 31 (77.5) 43 (50.6)
Total 45 (100) 40 (100) 99 (100)
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follow-up visits; therefore, patients who had their SNS devices fitted more than 18 months post
randomisation will not have any complications recorded. There were five complications from the
temporary SNS operation: (1) neurological, (2) haemorrhoid discomfort, (3) intermittent flare of eczema
at SNS dressing site, (4) lack or loss of efficiency, and (5) device failure/separation. There were eight
complications from the permanent SNS operation: (1) lead migration/fragmentation, (2) pain at battery
site, (3) lack or loss of efficiency, (4) transient anal/rectal pain, (5) rectal/anal pain on defaecation,
(6) neurological, (7) cardiorespiratory and (8) device reoperation: replacement of SNS wire. There were
88 complications across 33 patients in the FENIX MSA arm (Table 13).
The adjusted model odds ratios can be seen in Table 14. The model results show a statistically significant
difference in the odds of a complication between the two treatment arms, with an adjusted odds ratio
of 12.91 (95% CI 2.75 to 60.68; p = 0.004). The random effect with respect to surgeon (i.e. the ‘random
intercept’) was 0.79 (SE 1.38), and the random effect with respect to the interaction between surgeon and
the difference between treatments (i.e. the ‘random slope’) was < 0.0001 (SE 2.17).
The time from randomisation to operation is presented in Figure 2. There is a large difference between
the arms, with four patients in the SNS arm not having a permanent operation within 18 months of
randomisation; therefore, the model results may be biased against the FENIX MSA arm as patients in
TABLE 13 Complications in FENIX arm
Complication Total, n (%)
Worsening constipation/obstructed defecation 18 (20.5)
Othera 17 (19.3)
Transient anal/rectal pain 14 (15.9)
Device erosion 8 (9.1)
Wound infection 7 (8.0)
Device explant/reoperation 7 (8.0)
Implant infection 5 (5.7)
Bleeding/wound haematoma 4 (4.5)
Neurological 3 (3.4)
Lack or loss of efficiency 3 (3.4)
Urinary retention 1 (1.1)
Device failure/separation 1 (1.1)
Total 88 (100)
a Other complications:
l increase discharge of wound and breakdown
l small sinus around perianal area
l right upper quadrant pain
l wound dehiscence
l small swelling at edge of wound
l poor evacuation/constipation (n= 3)
l pain lasting 4 weeks
l pinching of skin around device
l superficial dehiscence of wound not exposing muscle or the implant
l pain at base of right back
l lack of control of bowels
l wound pain
l covering stoma
l wound still not healed following explant, fistula
l bleeding from prolapse.
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this arm will have had longer postoperative follow-up and, therefore, longer exposure to the risk
of postoperative complication within the trial follow-up period. However, Table 12 shows the number
of days from operation to first complication and this shows that most complications occurred within
3 months, with some happening a long time after the operation. As seen in Figure 2, most SNS patients
were followed up for > 3 months post randomisation.
Appendix 1, Figure 32, shows the empirical probability plot for the postoperative complications model,
which can be used to compare actual Pearson residuals with expected Pearson residuals. The y-axis is
the actual Pearson residual value, the x-axis is the empirical median Pearson residual expected under our
fitted model assumptions. Each dot represents the actual Pearson residual for an individual patient. If the
model fitted perfectly we would expect all of the dots to lie on the reference line. The band in Figure 32
represents the interval between the empirical 2.5th percentile and 97.5th percentile empirical Pearson
residual. No values lie outside this region, indicating that we do not have any substantial outliers.
Appendix 1, Figure 33, presents the plot of exponentiated delta-betas (y-axis) versus patient identifier.
Exponentiated delta-betas further from 1 indicate greater influence of the observation on the
estimated treatment effect. There does not appear to be any unusually influential observations in the
delta-beta plot.
Secondary end point: device explants
The number of devices in situ and explanted within 18 months of randomisation can be seen in Table 15.
The mean number of days from device implant to explant was 164 (SD 168) and the median number of
days was 112 (range 0–449).
Figure 5 shows the periods of time (measured from randomisation) for which each patient had a
permanent device in situ. The mean number of days from implant to explant was 164 (SD = 168) and
the median number of days was 112 (range 0–449). As there were no explants in the SNS arm, the
device explants end point has not been modelled because any regression models would not converge.
TABLE 14 Postoperative complications regression model
Effect Odds ratio Odds ratio 95% CI p-value
FENIX MSA (vs. SNS) 12.91 2.75 to 60.68 0.0042
Male (vs. female) 1.04 0.03 to 36.87 0.98
Baseline CCIS > 10 points (vs. baseline CCIS ≤ 10 points) 0.79 0.11 to 5.59 0.81
Anal sphincter defect ≤ 90° (vs. no defect) 1.43 0.44 to 4.68 0.55
Anal sphincter defect > 90° to ≤ 180° (vs. no defect) 0.41 0.03 to 6.78 0.53
TABLE 15 Device status at 18 months post randomisation
Device status FENIX MSA, n (%) SNS, n (%) Total, n (%)
Device in situ 30 (60.0) 24 (49.0) 54 (54.5)
Device explanted 15 (30.0) 0 (0.0) 15 (15.2)
No device fitted 5 (10.0) 21 (42.9) 26 (26.3)
Device implanted more than 18 months post randomisation 0 (0.0) 4 (8.2) 4 (4.0)
Total 50 (100) 49 (100) 99 (100)
RESULTS
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The reasons for explant are given in Table 16 and include participant intolerance (n = 4), device
erosion/migration and infection, implant infected and visible through the skin, device eroded, infection/
erosion (n = 3), rectal perforation the device was removed/no implant, chronic sinus infection,
participant did not have adequate response, and device malfunction.
Secondary end point: Cleveland Clinic Incontinence Score
The CCIS assesses five parameters associated with incontinence: incontinence to solid, incontinence to
liquid, incontinence to gas, use of pads and lifestyle restrictions. Each parameter is scored 0–4 with
‘0’ for never and ‘4’ for every day. The five parameters are added to give a total score out of 20, with a
lower score indicating a better QoL.
Summary measures of the CCIS split by time point and treatment arm are given in Table 17.
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FIGURE 5 Time to explant: (a) FENIX MSA; and (b) SNS. Dashed line indicates that patient had device explanted.
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TABLE 16 Reasons for explant
Reason Days from randomisation to explant
Participant intolerance 257
Device erosion/migration + infection 16
Implant infected and is visible through the skin 154
Participant did not have adequate response 399
Device eroded 350
Infection/erosion of FENIX beads SAE 14
Rectal perforation the device was removed/no implant 0
Infection and erosion, device explanted 7
Infection erosion 69
Chronic sinus infection 169
Participant did not have adequate response 409
Device malfunction 449
SAE, serious adverse event.
TABLE 17 Crude summaries of CCIS at baseline and at 6, 12 and 18 months post randomisation
CCIS (points) FENIX MSA SNS Total
Baseline
Mean (SD) 14.4 (3.15) 14.7 (2.95) 14.6 (3.04)
Median (range) 14.5 (6.0–20.0) 15.0 (9.0–20.0) 15.0 (6.0–20.0)
Missing 4 3 7
n 46 46 92
6 months post randomisation
Mean (SD) 11.7 (4.61) 13.8 (3.45) 12.8 (4.16)
Median (range) 12.0 (2.0–20.0) 14.0 (7.0–20.0) 13.0 (2.0–20.0)
Missing 15 10 25
n 35 39 74
12 months post randomisation
Mean (SD) 11.8 (4.86) 12.9 (3.78) 12.3 (4.37)
Median (range) 12.0 (3.0–20.0) 13.0 (5.0–20.0) 12.0 (3.0–20.0)
Missing 15 15 30
n 35 34 69
18 months post randomisation
Mean (SD) 11.1 (4.35) 12.1 (4.55) 11.6 (4.45)
Median (range) 11.0 (3.0–17.0) 12.5 (1.0–19.0) 12.0 (1.0–19.0)
Missing 20 15 35
n 30 34 64
SD, standard deviation.
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Secondary end point: EuroQol-5 Dimensions, five-level version
The EQ-5D-5L is made up of 5 dimensions (mobility, self-care, usual activities, pain/discomfort and
anxiety/depression), each of which has 5 levels (no problems, slight problems, moderate problems,
severe problems and extreme problems). These levels can be combined to calculate an index value,
which ranges from 1 (best possible health), through 0 (death) to –0.594 (worse than death).
Summary measures of the EQ-5D-5L index values, and the EQ-5D-5L Visual Analogue Scale (VAS)
scores, split by time point and treatment arm, are given in Table 18.
TABLE 18 Crude summaries of EQ-5D-5L score and EQ-5D-5LVAS at baseline and at 6, 12 and 18 months post randomisation
Variable FENIX MSA SNS Total
EQ-5D-5L score
Baseline
Mean (SD) 0.666 (0.256) 0.647 (0.261) 0.657 (0.257)
Median (range) 0.740 (–0.02–1.00) 0.736 (–0.05–1.00) 0.736 (–0.05–1.00)
Missing 4 3 7
n 46 46 92
6 months post randomisation
Mean (SD) 0.687 (0.225) 0.639 (0.295) 0.662 (0.263)
Median (range) 0.736 (–0.02–1.00) 0.732 (–0.22–1.00) 0.736 (–0.22–1.00)
Missing 12 7 19
n 38 42 80
12 months post randomisation
Mean (SD) 0.684 (0.258) 0.673 (0.263) 0.679 (0.259)
Median (range) 0.750 (–0.06–1.00) 0.752 (00.023–1.00) 0.750 (–0.06–1.00)
Missing 13 13 26
n 37 36 73
18 months post randomisation
Mean (SD) 0.660 (0.258) 0.683 (0.255) 0.672 (0.255)
Median (range) 0.732 (0.054–1.00) 0.743 (–0.05–1.00) 0.735 (–0.05–1.00)
Missing 20 17 37
n 30 32 62
EQ-5D-5L VAS score
Baseline
Mean (SD) 65.7 (20.3) 66.8 (24.8) 66.2 (22.5)
Median (range) 70.0 (0.00–95.0) 70.0 (5.00–100) 70.0 (0.00–100)
Missing 2 5 7
n 48 45 93
continued
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Secondary end point: faecal incontinence quality of life
The FIQoL questionnaire is composed of 29 items that make up four scales: lifestyle (10 items), coping/
behaviour (9 items), depression/self-perception (7 items) and embarrassment (3 items). Scales range
from 1 to 5 and scale scores are derived by averaging the response to all items in the scale. A lower
score indicates a lower functional QoL.
Summary measures of the four FIQoL domains split by time point and treatment arm are provided
in Table 19.
Secondary end point: Obstructed Defecation Score
The ODS consists of five items: excessive straining, incomplete rectal evacuation, use of enemas and/or
laxatives, vaginal-anal-perineal digitations, and abdominal discomfort and/or pain. Each item is graded
from 0 to 4, with scores ranging from 0 (no symptoms) to 20 (very severe symptoms), meaning that a
lower score indicates better QoL.
Summary measures of the total ODS split by time point and treatment arm are presented in Table 20.
Secondary end point: Short Form questionnaire-12 items
The SF-12 version 2 is a generic health survey that measures eight health domains: physical
functioning, role – physical, bodily pain, general health, vitality, social functioning, role – emotional and
mental health. The Physical Component Summary (PCS) and Mental Component Summary (MCS)
TABLE 18 Crude summaries of EQ-5D-5L score and EQ-5D-5LVAS at baseline and at 6, 12 and 18 months post randomisation
(continued )
Variable FENIX MSA SNS Total
6 months post randomisation
Mean (SD) 66.9 (19.6) 72.7 (19.3) 69.9 (19.5)
Median (range) 70.0 (30.0–95.0) 75.0 (15.0–95.0) 75.0 (15.0–95.0)
Missing 11 7 18
n 39 42 81
12 months post randomisation
Mean (SD) 65.5 (21.1) 73.2 (19.7) 69.4 (20.6)
Median (range) 70.0 (10.0–96.0) 75.0 (20.0–100) 72.5 (10.0–100)
Missing 14 13 27
n 36 36 72
18 months post randomisation
Mean (SD) 66.0 (19.6) 72.1 (14.0) 69.2 (17.0)
Median (range) 67.5 (20.0–95.0) 70.0 (33.0–100) 70.0 (20.0–100)
Missing 20 16 36
n 30 33 63
SD, standard deviation.
RESULTS
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TABLE 19 Crude summaries of FIQoL domains at baseline and at 6, 12 and 18 months post randomisation
FIQoL domain FENIX MSA SNS Total
Lifestyle (baseline)
Mean (SD) 2.17 (0.864) 2.12 (0.887) 2.15 (0.871)
Median (range) 2.00 (1.00–3.80) 2.00 (1.00–3.90) 2.00 (1.00–3.90)
Missing 5 5 10
n 45 44 89
Lifestyle (6 months post randomisation)
Mean (SD) 2.64 (1.09) 2.39 (0.918) 2.51 (1.01)
Median (range) 2.70 (1.00–4.00) 2.30 (1.00–4.00) 2.50 (1.00–4.00)
Missing 13 11 24
n 37 38 75
Lifestyle (12 months post randomisation)
Mean (SD) 2.74 (1.08) 2.35 (1.03) 2.56 (1.06)
Median (range) 3.05 (1.00–4.00) 2.30 (1.00–3.90) 2.75 (1.00–4.00)
Missing 14 17 31
n 36 32 68
Lifestyle (18 months post randomisation)
Mean (SD) 2.73 (1.03) 2.62 (1.02) 2.68 (1.02)
Median (range) 2.90 (1.00–4.00) 2.90 (1.00–4.00) 2.90 (1.00–4.00)
Missing 21 22 43
n 29 27 56
Coping (baseline)
Mean (SD) 1.44 (0.534) 1.50 (0.616) 1.47 (0.573)
Median (range) 1.33 (1.00–3.67) 1.33 (1.00–3.44) 1.33 (1.00–3.67)
Missing 9 9 18
n 41 40 81
Coping (6 months post randomisation)
Mean (SD) 2.04 (0.984) 1.63 (0.610) 1.81 (0.818)
Median (range) 1.67 (1.00–4.00) 1.56 (1.00–3.22) 1.56 (1.00–4.00)
Missing 23 16 39
n 27 33 60
Coping (12 months post randomisation)
Mean (SD) 2.24 (1.02) 1.57 (0.671) 1.91 (0.923)
Median (range) 2.11 (1.00–4.00) 1.44 (1.00–3.22) 1.56 (1.00–4.00)
Missing 23 22 45
n 27 27 54
continued
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TABLE 19 Crude summaries of FIQoL domains at baseline and at 6, 12 and 18 months post randomisation (continued )
FIQoL domain FENIX MSA SNS Total
Coping (18 months post randomisation)
Mean (SD) 1.94 (0.895) 1.97 (0.820) 1.96 (0.847)
Median (range) 1.67 (1.00–3.89) 2.11 (1.00–3.44) 1.89 (1.00–3.89)
Missing 30 28 58
n 20 21 41
Depression (baseline)
Mean (SD) 2.52 (0.956) 2.33 (0.864) 2.43 (0.911)
Median (range) 2.14 (1.14–4.29) 2.29 (1.00–4.29) 2.14 (1.00–4.29)
Missing 11 11 22
n 39 38 77
Depression (6 months post randomisation)
Mean (SD) 2.74 (1.07) 2.48 (0.891) 2.60 (0.978)
Median (range) 2.36 (1.43–4.43) 2.43 (1.14–4.14) 2.43 (1.14–4.43)
Missing 24 19 43
n 26 30 56
Depression (12 months post randomisation)
Mean (SD) 2.70 (1.11) 2.57 (0.898) 2.64 (1.01)
Median (range) 2.29 (1.14–4.29) 2.64 (1.29–4.00) 2.43 (1.14–4.29)
Missing 20 21 41
n 30 28 58
Depression (18 months post randomisation)
Mean (SD) 2.89 (0.948) 2.72 (0.981)








Mean (SD) 1.74 (0.699) 1.64 (0.640) 1.69 (0.668)
Median (range) 1.67 (1.00–3.33) 1.33 (1.00–3.33) 1.67 (1.00–3.33)
Missing 4 2 6
n 46 47 93
Embarrassment (6 months post randomisation)
Mean (SD) 2.12 (0.996) 1.87 (0.789) 1.99 (0.897)
Median (range) 1.67 (1.00–4.00) 1.67 (1.00–4.00) 1.67 (1.00–4.00)
Missing 11 7 18
n 39 42 81
RESULTS
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TABLE 19 Crude summaries of FIQoL domains at baseline and at 6, 12 and 18 months post randomisation (continued )
FIQoL domain FENIX MSA SNS Total
Embarrassment (12 months post randomisation)
Mean (SD) 2.20 (0.970) 1.87 (0.791) 2.04 (0.894)
Median (range) 2.33 (1.00–4.00) 1.67 (1.00–3.67) 1.83 (1.00–4.00)
Missing 13 12 25
n 37 37 74
Embarrassment (18 months post randomisation)
Mean (SD) 2.24 (1.02) 1.99 (0.827) 2.11 (0.926)
Median (range) 2.33 (1.00–4.00) 1.83 (1.00–4.00) 2.00 (1.00–4.00)
Missing 21 17 38
n 29 32 61
SD, standard deviation.
TABLE 20 Crude summaries of ODS at baseline and at 6, 12 and 18 months post randomisation
ODS FENIX MSA SNS Total
Baseline
Mean (SD) 7.44 (3.78) 7.09 (3.62) 7.27 (3.68)
Median (range) 7.00 (2.00–18.0) 8.00 (2.00–17.0) 7.00 (2.00–18.0)
Missing 5 6 11
n 45 43 88
6 months post randomisation
Mean (SD) 9.10 (4.83) 7.53 (3.48) 8.40 (4.33)
Median (range) 8.00 (0.000–20.0) 7.00 (0.000–16.0) 8.00 (0.000–20.0)
Missing 10 17 27
n 40 32 72
12 months post randomisation
Mean (SD) 8.34 (4.86) 7.52 (3.75) 7.94 (4.34)
Median (range) 8.00 (1.00–20.0) 8.00 (2.00–15.0) 8.00 (1.00–20.0)
Missing 15 16 31
n 35 33 68
18 months post randomisation
Mean (SD) 8.58 (4.77) 6.90 (4.34) 7.67 (4.58)
Median (range) 8.00 (0.000–18.0) 6.00 (0.000–16.0) 7.00 (0.000–18.0)
Missing 24 18 42
n 26 31 57
SD, standard deviation.
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measures are calculated using a combination of the eight domains. Scores are calibrated so that the
mean score is 50 with a standard deviation (SD) of 10 in the 2009 general US population. All scores
range from 0 to 100, with a higher value indicating better functioning and well-being.
Summary measures of the SF-12 PCS and MCS components split by time point and treatment arm are
presented in Table 21.
TABLE 21 Crude summaries of SF-12 PCS and MCS components at baseline and at 6, 12 and 18 months post randomisation
SF-12 component FENIX MSA SNS Total
PCS (baseline)
Mean (SD) 44.9 (9.36) 46.9 (10.2) 45.9 (9.78)
Median (range) 46.5 (18.6–61.2) 47.3 (23.6–64.0) 47.3 (18.6–64.0)
Missing 3 1 4
n 47 48 95
PCS (6 months post randomisation)
Mean (SD) 46.2 (9.96) 47.7 (9.71) 47.0 (9.80)
Median (range) 45.6 (27.6–68.5) 48.7 (23.9–70.0) 47.1 (23.9–70.0)
Missing 11 7 18
n 39 42 81
PCS (12 months post randomisation)
Mean (SD) 47.1 (9.64) 47.4 (9.49) 47.2 (9.50)
Median (range) 49.0 (26.7–65.3) 49.8 (20.3–64.1) 49.2 (20.3–65.3)
Missing 12 12 24
n 38 37 75
PCS (18 months post randomisation)
Mean (SD) 43.9 (10.9) 47.0 (10.4) 45.5 (10.7)
Median (range) 43.9 (26.9–59.7) 46.8 (23.7–63.3) 46.6 (23.7–63.3)
Missing 19 16 35
n 31 33 64
MCS (baseline)
Mean (SD) 41.2 (11.4) 41.2 (11.2) 41.2 (11.2)
Median (range) 42.7 (22.8–61.8) 40.9 (17.0–63.5) 41.3 (17.0–63.5)
Missing 3 1 4
n 47 48 95
MCS (6 months post randomisation)
Mean (SD) 41.6 (13.2) 42.5 (12.5) 42.0 (12.8)
Median (range) 40.8 (15.8–62.0) 45.2 (15.4–61.2) 43.1 (15.4–62.0)
Missing 10 7 17
n 40 42 82
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Registered training cases
Prior to randomising patients in the study, all surgeons were required to have experience of a minimum
of one observed FENIX MSA procedure and two FENIX MSA procedures under proctorship. Surgeons
who did not have this experience before study participation joined the registration phase of the study in
which the first two eligible patients providing consent were registered to receive FENIX MSA implants.
These two operations, performed under proctorship, were considered training cases and were not
included in the main study.
A total of 23 patients were registered as training cases for the FENIX MSA operation. Of these 23 patients,
22 received the FENIX operation and one withdrew, giving the reason as travelling scheduled for after the
surgery date; the patient withdrew after discussing with a research nurse advice about travelling post
surgery, and decided not to risk discomfort and complications.
There was one operative complication, with the complication described as ‘Perf skin posterior.
Primary repair’.
Only complications that occurred within 30 days of the operation were reported for the registered
training cases. There were 22 postoperative complications across 13 patients:
l wound infection (n = 7)
l transient anal/rectal pain (n = 3)
l wound dehiscence (n = 2)




l urinary tract infection
l incomplete emptying of bladder on micturition
l prickly sensation
l incomplete emptying
l superficial wound dehiscence.
TABLE 21 Crude summaries of SF-12 PCS and MCS components at baseline and at 6, 12 and 18 months post randomisation
(continued )
SF-12 component FENIX MSA SNS Total
MCS (12 months post randomisation)
Mean (SD) 41.6 (13.3) 43.8 (11.7) 42.7 (12.5)
Median (range) 41.9 (20.5–60.5) 43.2 (17.4–62.4) 43.2 (17.4–62.4)
Missing 12 12 24
n 38 37 75
MCS (18 months post randomisation)
Mean (SD) 43.5 (12.5) 44.3 (12.2) 43.9 (12.2)
Median (range) 41.2 (15.2–63.1) 46.7 (19.2–69.6) 44.6 (15.2–69.6)
Missing 19 16 35
n 31 33 64
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Chapter 3 Health economics
This section outlines the approach to the manipulation and analysis of the health economic datafrom the SaFaRI trial for the purpose of conducting an economic evaluation of the FENIX device.
The economic evaluation followed the NICE reference case26 and, hence, was a cost–utility analysis
presenting cost per incremental QALY from the perspective of the health-care and personal social
service’s provider. The evaluation used both trial-based and model-based analyses, and adopted a
lifetime horizon. A model was required given that the likely costs and benefits of the interventions
continue to accrue after the trial time horizon (18 months). Our primary analysis is based on the
combined trial and model results, but we also report cost-effectiveness at the trial end.
The evaluation assumes a willingness-to-pay threshold (λ) of £20,000 per QALY gain, and estimates the
incremental costs and benefits of the FENIX magnetic anal sphincter (MAS) device versus usual SNS
for adult FI.
Methods: trial
Health utility and quality-adjusted life-year calculation
Health-related quality-of-life (HRQoL) data to enable QALY calculations were collected during the trial
at baseline and at 6, 12 and 18 months post randomisation. Data were available on the EQ-5D-5L27,28
and the SF-12 [Short Form questionnaire-6 Dimensions (SF-6D)].29
The primary analysis is based on the EQ-5D-5L direct valuation.30 The secondary analysis estimated
QALYs based on the SF-12 (SF-6D) instrument. A supplementary analysis reported results based on the
EQ–5D-5L crosswalk (to the EQ-5D-3L).31
The QALY calculation was estimated on an area under the curve approach, adopting the following
assumptions:
l All follow-ups were carried out at the exact, prespecified time period (0, 6, 12 and 18 months).
l A patient who died with their last EQ-5D-5L observation as positive had a linear fall in HRQoL from
this point until death.
l A patient who died with their last EQ-5D-5L observation as negative had this constant level of
HRQoL from this point until death.
Notation: E0 = baseline utility, E6 = utility at 6 months, E12 = utility at 12 months, E18 = utility at
18 months, t = duration in each health state in days. If EQ-5D-5L was present at baseline, 6, 12 and
18 months’ follow-up, QALYs were calculated by:
Total QALYs = (((t/365) × (E0 + E6))/2) + (((t/365) × (E6 + E12))/2) + (((t/365) × (E12 + E18))/2). (1)
Resource use and costs
The perspective for the costs was the health and social care provider (i.e. wider costs, such as
productivity loss or out-of-pocket expenses, were not included).
We used a combination of patient-reported data, CRF data capture and published estimates to derive
costs during the evaluation. The general approach, individual unit costs and costing assumptions were
verified with and refined following input from the lead clinician on the trial. The cost categories and
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overall approach to establishing the cost of each intervention over the trial period and the associated
source of resource use/costs is as follows:
1. device costs – taken from publications and online resources
2. procedure costs – taken from national tariffs and online resources
3. medications – based on patient report
4. primary/social care – based on patient report
5. secondary care after the initial procedure – generated by attributing costs to explants,
complications and further treatments/surgery.
The strategy for secondary care resource use capture deviates from the strategy that was planned.
We had originally aimed to request NHS digital data to capture this aspect of resource; however, as a
result of the early stopping of the trial, the associated reduction in research funding and the resultant
limited sample size, this was considered to be impractical and was not pursued. This decision was made
following consultation with the trial team. Since secondary care costs (hospital visits and stay) were
not captured directly elsewhere in the trial, we elected to capture them via the length of stay of the
original procedure and by costing subsequent explants, complications and surgeries.
The combined device and procedure costs are included in Table 22 and include the device-specific cost
and a day-case rate for insertion of a generic neurostimulator for treatment of FI costs. These costs are
TABLE 22 Device and procedure costs
Item
Cost




Temporary device cost £680 Hounsome and Roukas32 N/A
Temporary device
procedure costs
£1819 Insertion of neurostimulator for treatment of faecal incontinence,
day case (FF47Z) (NHS Reference Costs 2017–201833)
N/A
Excess bed-day cost
for stays > 1 day
£362 Insertion of neurostimulator for treatment of faecal
incontinence, elective short stay excess bed-day (FF47Z)
(NHS Reference Costs 2017–201833)
N/A
SNS: permanent
Permanent device cost £7750 Hounsome and Roukas32 N/A
Permanent procedure
costs
£1819 Insertion of neurostimulator for treatment of faecal




for stays > 1 day
£362 Insertion of neurostimulator for treatment of faecal
incontinence, elective short stay excess bed-day (FF47Z)
(NHS Reference Costs 2017–201833)
N/A
FENIX: MSA
Sizing tool £300 URL: www.io.nihr.ac.uk/wp-content/uploads/migrated/
2220.838f0fdf.FENIXforfaecalincontinenceFINAL.pdf
(accessed 12 February 2021)
N/A
Device cost £4000 URL: www.io.nihr.ac.uk/wp-content/uploads/migrated/
2220.838f0fdf.FENIXforfaecalincontinenceFINAL.pdf
(accessed 12 February 2021)
N/A
Procedure cost £1819 Assumed same as SNS: insertion of neurostimulator for
treatment of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
N/A
Excess bed-day cost
for stays > 1 day
£362 Insertion of neurostimulator for treatment of faecal
incontinence, elective short stay excess bed-day (FF47Z)
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fixed, except for the cost of the hospital stay. Any nights spent in hospital (including the first night)
were costed using the unit cost shown for an excess bed-day. Data collected in the trial (e.g. relating
to theatre time during procedure) may have allowed for a more granular approach to costing the
procedure; however, given the small sample sizes, it may be prone to undue bias from outliers; thus,
we opted to use NHS reference cost tariffs.
An operative form was completed for each patient following the procedure. The form captures
operation details, including which procedure the patient received (temporary SNS and/or permanent
SNS, or FENIX MSA) and any intraoperative complications that may occur. The form also reports
whether patients receive a local, general or spinal anaesthetic, and whether or not the procedure has
been completed. Furthermore, a 2-week postoperative review was issued for each patient to gather
information on whether or not patients progress to permanent SNS, if they were randomised to
receive temporary SNS, whether or not the device they received is still in situ and a reason provided if
the device has been explanted. This discharge form was also used to record whether or not patients
who have been discharged receive further surgery or suffer from any postoperative complications.
Follow-up forms were completed by the local research teams at 6, 12 and 18 months following
randomisation and asked for similar patient information. Individual complications and further surgeries
were costed using the unit costs given in Appendix 1, Tables 39 and 40, respectively. With the exception
of explantation, we assumed that the costs of any intraoperative complications were captured in the
length of stay of the initial procedure.
At baseline and at 6-month, 12-month and 18-month follow-up, patients were provided with a specially
designed form to report on their (primary and social) health-care resource use in the past 3 months:
general practitioner (GP), practice nurse, district nurse, physiotherapist, occupational therapist, counsellor
in the GP surgery visits, clinic (non-hospital) by telephone/e-mail or at home. They were also asked if
they received support from social services, including meals-on-wheels deliveries, laundry services, care
workers/help at home or social worker visits, and the frequency of this support. Furthermore, they
were asked to provide information on the use of community/residential services, including any visits
and overnight stays at convalescent homes, nursing homes and day centres. Patients were also asked to
note what medication relating to their FI they were taking on a regular basis. Unit costs for medications
are listed in Appendix 1, Table 41, and for primary care/social care in Appendix 1, Tables 42 and 43. We
assumed that any follow-up care costs associated with the interventions are captured in the self-reported
primary care use data. The 3-month recall data were multiplied by two to obtain 6-month values.
In a majority of cases, unit costs were based on national resources such as the Personal Social Services
Research Unit (PSSRU) report, NHS Reference Costs and the Electronic Market Information Tool
(eMIT). Elsewhere, we used other web resources and previous publications as the basis for unit costs
for health-care resources. All costs are presented in Great British pounds and the price year is 2018
(costs are inflated to 2018/19 prices where necessary using the Consumer Price Index for health).
Analysis
The main analysis was based on an intention-to-treat principle. The trial analysis produced ICERs over
the trial period (18 months). We used seemingly unrelated regression34,35 to account for the expected
correlation between costs and QALYs while controlling for any baseline imbalances. Although we had
planned to use the same covariates as the statistical analysis, analyses were run with no adjustment,
and subsequently adjusting for baseline EQ-5D-5L and (primary/social care) costs given the data
limitations. The regression models estimated costs and QALYs that will allow the calculation of ICERs.
Our primary analysis incorporated multiple imputation (MI) to impute missing data; however, we also
conducted a complete-case analysis. Individuals with missing EQ-5D-5L items were not allocated a
utility index score. Where missing values could not be dealt with in the manner described above
(see Health utility and quality-adjusted life-year calculation), we conducted MI as part of the model
estimation procedure. Costs were imputed for each individual at each time point for the following
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categories: (1) total primary care and social care costs, (2) total secondary care costs and (3) total
medication costs.
We present a range of sensitivity analyses to explore the impact of the assumptions made in the base
case analysis on the cost-effectiveness estimates. These include the methods used to assess utility in
the trial and model covariates. We also conducted non-parametric bootstrapping to calculate the
probability that FENIX was cost-effective at the trial end.
The final cost and QALY estimates at 18 months were added to the beginning of the decision model
time horizon, and additional costs and benefits were estimated in the model from 18 months over
a lifetime.
Methods: decision model
We generated a de novo decision-analytic model to estimate cost per QALY estimates over a lifetime
horizon. In addition to extending the evaluation period to a relevant horizon, the model also allows the
exploration of uncertainty in the parameter estimates, individually and jointly, as part of a probabilistic
sensitivity analysis (PSA). The latter will allow the production of cost-effectiveness acceptability
curves (CEACs)36 and estimates of the value of information (further research). The modelling was
conducted in Microsoft Excel® 2016 (Microsoft Corporation, Redmond,WA, USA).
Model type, cycle length, structure and health states
The model is a Markov model describing a simplified patient pathway from the end of the trial period
(18 months) over a lifetime in terms of discrete health states. The average age of the patients at the
model start reflected that of the trial participants (62 years). Patients move between these health
states at the end of every model cycle (in this case, 1 year) according to prespecified transition
probabilities.
The structure of the decision model is shown in Figure 6. The structure was informed by other models
used in this population32,37 and was finalised following input from the lead clinician.
In the model, we defined the health states as being related to effectiveness according to the
percentage improvement on baseline CCIS (100–76% improvement, 75–51% improvement, ≤ 50%
improvement) and whether or not the device is still in situ (device explant). ‘Better’ health states
(i.e. higher percentage of improvement) are associated with lower costs and higher QoL. Although we
did not a priori expect the interventions to have an impact on survival, because the model is over a
lifetime horizon, we also modelled background, all-cause mortality (dead health state).
Each health state is associated with a specific average cost and HRQoL (utility value). A hypothetical
cohort of FI patients for each treatment arm was distributed between these health states at model
start with the distribution reflecting that of the trial sample and intervention effectiveness/functionality
at 18 months. These patients moved between health states at the end of each model cycle, with the
likelihood of this movement determined by transition probabilities that reflected treatment effectiveness –
more specifically, loss of effectiveness over time – and mortality rates.
We assumed that 18 months after initial implant, effectiveness could only deteriorate, and thus
patients would be transited downwards in terms of percentage improvement from baseline. We also
assumed that once explantation had occurred, another device (either SNS or FENIX) would not be
implanted. Patients receiving FENIX initially are unlikely to receive another FENIX device following
explantation owing to clinical viability. While it is possible that initial FENIX implants could be replaced
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by SNS devices and that initial SNS devices could be replaced by either another SNS device or a
FENIX device, the patient numbers on these pathways would be relatively small. Incorporating these
possibilities would require additional modelling complexity, and the additional burden of data
requirements (e.g. effectiveness of second implants) was unlikely to be met, and thus additional
assumptions would be required. We also included in the explant health state those in the SNS group
who did not have a permanent implant. The explant health state was therefore capturing ‘conservative
management’ for those without a device in situ.
The durability of the FENIX device is unknown and the device will in theory continue to function in the
long term until a fault or infection occurs. However, the SNS device has a finite battery life (approximately
between 5 and 7 years), at which point explantation, battery replacement and implantation is required.
We reflected this in a submodel for SNS. After battery replacement, patients were subject to the same
distribution among effectiveness categories as observed in the trial arm at 18 months (rather than
immediately post procedure) for those that had the permanent device implanted. We did not include
another battery replacement at 14 years in the base-case model because of the added modelling
complexity and the small proportion likely to have a device in situ but we tested this in simplified
sensitivity analyses. Other modelling assumptions are set out in the parameter tables.
Parameter values: transition probabilities
The decision model required a set of parameter values that defined the movement of the cohort
around the model (transition probabilities are shown in Table 23). Where possible, the transition rates
for the model were estimated from the randomised controlled trial (RCT) data (observed data rather
than imputed). We used the end distribution of trial patients per arm across percentage improvement
groups as the starting proportions in these groups at model start. We used trial data on transition
rates between these percentage improvement groups during the trial to specify a rate beyond
18 months. As a result of the limited sample size, we were unable to do this in a robust way per
intervention arm, so we assumed these rates to be the same across arms.
TABLE 23 Parameter values: transition probabilities and event rates
Parameter Value SE Distributiona Source/reference
Common parameters
Starting age of model
cohort (years)
62 N/A Fixed Mean of the trial sample
Survival Age
dependent




13,126 N/A Fixed The NIHR Horizon Scanning Centre (2012) News Brief:
FENIX™ Continence Restoration System for severe
chronic faecal incontinence20
80 new adults per 100,000 population
30 of these referred to surgical specialist
Adult population in England= 43,752,473





10 N/A Fixed Assumed
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We applied parametric survival curves to the time-to-explant data from the trial and extrapolated
this beyond 18 months. The survival analysis indicated no increase in hazard over time, and thus we
estimated a constant hazard rate using the exponential distribution in Stata® version 15 (StataCorp LP,
College Station, TX, USA). There were no explants in the SNS group, but a clinical expert felt that this
was an artefact of the sample size; hence, we used the same explant rate for both intervention groups.
Following input from the same clinical expert, we assumed that survival in the FI population was not
significantly different from survival in the general population and, thus, used Office for National
Statistics mortality data38 to model this. We also assumed that neither the interventions nor the
percentage improvement had an impact on survival.
TABLE 23 Parameter values: transition probabilities and event rates (continued )
Parameter Value SE Distributiona Source/reference
FENIX
Starting proportions Trial data at 18 months
100–76% improvement 0.00 N/A Dirichlet
75–51% improvement 0.16 N/A Dirichlet
≤ 50% improvement 0.39 N/A Dirichlet
Device explant 0.42 N/A Dirichlet




100–76% to 75–51% 0.167 N/A Dirichlet
100–76% to ≤ 50% 0.667 N/A Dirichlet
75–51% to ≤ 50% 0.800 N/A Dirichlet
Probability of explant 0.15 N/A Dirichlet
SNS
Starting proportions Trial data at 18 months
100–76% improvement 0.026 N/A Dirichlet
75–51% improvement 0.105 N/A Dirichlet
≤ 50% improvement 0.342 N/A Dirichlet
Device explant 0.526 N/A Dirichlet




100–76% to 75–51% 0.167 N/A Dirichlet
100–76% to ≤ 50% 0.667 N/A Dirichlet
75–51% to ≤ 50% 0.800 N/A Dirichlet Survival curve based on trial data
Probability of explant 0.15 N/A Dirichlet Assumed same rate as FENIX
Probability of battery
replacement
1 N/A Fixed Battery replacement every 7 years based on
triangulation of several sources and clinical opinion32,39,40
EVPI, expected value of perfect information; N/A, not applicable.
a Fixed indicates the value did not vary in the PSA.
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Parameter values: health state utilities
Economic evaluations are designed to inform resource allocation decisions, thus the model used the
QALY outcome measure as prescribed by NICE. The estimation of QALYs requires the production of
utility weights for health states; these data were derived from the RCT (Table 24). We used linear
regression predicting EQ-5D-5L utility weights and health state groups as an explanatory categorical
variable. The regression used multiple observations per person and robust SEs to reflect this approach.
As the interventions were assumed not to influence survival, it was not considered necessary to adjust
utility values for age over the time horizon. There was no utility decrement for battery replacement as
this was assumed to be a ‘tunnel state’ straight to percentage CCIS improvement groups (i.e. patients
did not stay in this state for a sufficient period to incur substantive HRQoL loss).
Parameter values: costs
We generated health state costs from the trial data (see Table 24). As we expected, costs were at their
highest immediately after the initial procedure and then fell over time (with the exception of the battery
replacement for SNS). We used the 12-month and 18-month resource use data to estimate ongoing
health-care costs in the model. As it was unclear whether or not the trial forms captured ongoing
(conservative management) costs for the no device group, we generated a monthly cost following
TABLE 24 Parameter values: utilities and costs
Parameter Value SE Distribution Source/reference
Health state utility
100–76% improvement 0.96 0.0304 Beta Trial data
75–51% improvement 0.90 0.0429 Beta Trial data





0.64 0.0801 Beta Trial data
Health state costs (per year)
100–76% improvement £90.67 79.39 Gamma Trial data
75–51% improvement £248.99 154.45 Gamma Trial data
≤ 50% improvement £384.07 131.16 Gamma Trial data
Device explant £631.91 451.92 Gamma Trial data
Procedure and device costs
Device explant:
procedure cost
£1819 N/A Fixed Insertion of neurostimulator for treatment
of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
(assumed same for FENIX and SNS)
Battery replacement:
procedure cost
£1819 N/A Fixed Insertion of neurostimulator for treatment
of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
(assumed same for FENIX and SNS)
Battery replacement:
SNS device cost
£7750 N/A Fixed Hounsome and Roukas32
N/A, not applicable.
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discussion with the lead clinician (detailed in Table 24) and tested this in a sensitivity analysis. We used
the full set of cost data to estimate costs immediately post battery replacement, and this was anticipated
to capture any complication and additional surgery costs. The explantation of a device or replacement of a
battery led to the procedure costs outlined in Table 24.
Relevant costs for the evaluation include the FENIX device/SNS acquisition and procedure (including
length of hospital stay), costs of treating adverse events/complications, costs of device explants and
other surgery, and (for SNS) the cost of battery replacement. These are in addition to the health
state costs that were obtained from the trial data. All costs relating to other surgeries, explants and
complications within 18 months were observed/captured in the trial data, and thus were not modelled
here. After 18 months, complication costs were assumed to be captured within the other health states.
Unit costs were obtained from national sources including the PSSRU,41 the British National Formulary42
(BNF) and the NHS Reference Cost33 database. Internet searches were conducted for other cost elements.
Validation
We validated the model by checking the face validity of the model structure and parameter values with
other health economists and with the lead clinician. We tested the internal validity of the model by
checking that model outputs followed expectations when changes were made to certain parameter
values (e.g. that the cost-effectiveness of FENIX improved following an increase in the SNS device cost
or reduced following an increase in the probability of explant in the FENIX arm).
Analysis
The average costs and QALYs accrued during the trial period were inputted at the start of the model,
with further costs and benefits added to these over the model horizon. We generated a deterministic
ICER per QALY gained and a net monetary benefit (NMB) estimate at the model end. We tested these
estimates using prespecified sensitivity analyses to identify drivers of cost-effectiveness. We specified
distributions for certain parameter values (denoted in the parameter tables) and ran a PSA where
random parameters were selected from these distributions and inputted into the model over 10,000
Monte Carlo simulations. The 10,000 costs and QALY estimates generated from the PSA were plotted
on a cost-effectiveness plane and the average of these was used to calculate the probabilistic ICER.
We used estimates of NMB to determine the probability that FENIX was cost-effective compared with
SNS over a range of willingness-to-pay values on the CEAC. Since the CEAC indicates the probability
of cost-effectiveness, we can calculate the probability that the optimal treatment will not be cost-
effective. Using this information and the NMB provided by the alternative treatment (the net benefit
loss), we used the value of information framework43 to estimate the total population expected value of
perfect information (EVPI). The population EVPI is estimated using the expected net benefit loss per
person from the decision, the number of people with FI that would be eligible for the treatments per
year (annual incidence is estimated to be 13,126) and the period for which the FENIX versus SNS
decision is still relevant (here, we assumed this to be 10 years). The higher the EVPI value, the
greater the potential cost of uncertainty and the greater the incentive to conduct additional research
(e.g. further trials) to reduce that uncertainty prior to making a decision.
We used a NICE willingness-to-pay threshold of £20,000 per QALY to determine cost-effectiveness
(or NMB value of > 0). We used a half-cycle correction to reflect the expectation that health state
transitions can happen at any time during a model cycle. In accordance with current NICE recommendations,
costs and outcomes post year 1 were discounted at 3.5% per annum. The perspective remained that of
the health and personal social services provider.
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Descriptive results for the costs (and cost category) are shown by arm in Table 25. There is a relatively
modest difference in total cost between arms. However, there are notable differences in the individual
cost categories, with the FENIX procedure being much cheaper than the SNS procedure, but being
associated with significantly higher secondary care costs (for other complications and surgeries).
Descriptive statistics on costs (and by cost category) and utility by arm, time-point and sample are
included in Appendix 1, Table 44.
The length of stay varied between intervention arms (SNS: range 0 to 59 days, median 0 days, mean
1.43 days; FENIX: range 0 to 15 days, median 1 day, mean 1.39 days).
The economic evaluation results for the 18-month trial period are included in Table 26. Results are
presented for complete case and following MI using EQ-5D-5L valuation, EQ-5D-5L to 3L cross-walk
and SF-6D utility scores for alternative adjusted models.
For the EQ-5D-5L and SF-6D analyses, there were a total of 47 cases across both arms that met the
complete-case criteria (of which 42 cases were common across both the EQ-5D-5L and the SF-6D
complete cases), whereas the MI analysis sample total was 94 cases. Five of the original 99 cases were
dropped because they had no baseline data or only baseline data. In all analyses, FENIX was more
expensive in the trial period than SNS, although this was reduced in the imputed analyses. In all of the
EQ-5D-5L analyses, except for the complete-case, 3L cross-walk with adjustment (for age and baseline
utility), FENIX led to a QALY benefit compared with SNS. We present the results for adjustment for
operating surgeon, but because of the small sample sizes these figures are highly variable and cannot
be considered robust.
The ICER for the primary analysis (MI, direct EQ-5D-5L valuation with adjustment for age and baseline
utility) is £44,785.62 per QALY gained and is well above the £20,000 threshold. In this analysis, FENIX
was associated with modest additional costs and negligible incremental QALYs compared with SNS.
Uncertainty in the results was represented in the CEAC (Figure 7). At a willingness-to-pay threshold of
£20,000 per QALY gain, FENIX has a 41.3% chance of being cost-effective.
The supplementary analysis using MI and a cross-walk to derive EQ-5D-3L values yields a much higher
QALY gain and lower ICER for FENIX. The analyses based on the SF-6D indicated a QALY loss
associated with FENIX, which was therefore dominated.
TABLE 25 Cost breakdown
Cost categorya
FENIX (£) SNS (£)
Mean SE Mean SE
Procedure 6190.55 274.96 8176.49 926.80
Medication 65.48 20.02 31.47 7.91
Explants 541.83 122.65 503.13 119.97
Primary care 701.30 115.38 549.32 102.40
Secondary care 2663.85 1119.02 597.11 283.86
Total 10,163.01 1266.37 9857.51 888.44
a These values are based on the MI (n= 94), EQ-5D-5L, unadjusted analysis.
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TABLE 26 Cost-effectiveness at 18 months
Analysis


























































































































































































































































































































































































































































































































The proportion of patients distributed between the CCIS percentage improvement groups is shown in
Table 23 (parameter table). For both arms, a majority of patients were either in the < 50% improvement
group or did not have a device in situ. Where the device was in situ, the results appear to indicate a
slight benefit for the SNS group, with more patients in the 50–75% and > 75% improvement groups.
One patient in the FENIX arm had died by 18 months and, although this is unlikely to be attributable
to randomisation arm, we retained this patient in the analysis.
The costs and benefits estimated during the trial period were added to the start of the model and
assumed to be fixed in the base case deterministic analysis. In each simulation of the probabilistic
analysis, we used a bootstrapped cost and QALY generated from the trial data.
Decision modelling
The model Markov trace is included in Figure 8. This gives an indication of the predicted intervention
effectiveness and survival over time. There are very few noticeable differences in the curves over the
lifetime horizon. The kinks in the SNS figure show where those patients with a device in situ receive a
battery replacement at 7 years and the redistribution among CCIS percentage improvement groups.
The deterministic model results, including lifetime costs, QALYs and ICER, are presented in Table 27.
Estimated lifetime costs are higher in the SNS group, as are the QALYs. The ICER and NMB values
indicate that FENIX is not cost-effective over this time horizon (SNS is the optimal strategy). These
results are mirrored by the probabilistic results, where the ICER for SNS versus FENIX drops.
Figure 9 plots the 10,000 costs and QALYs from the Monte Carlo simulations. The results highlight
significant uncertainty in the model outputs. The ICER of the mean value falls just below the willingness-
to-pay threshold (for SNS minus FENIX). The uncertainty in the results is further represented in the
CEAC (Figure 10). At a willingness-to-pay threshold of £20,000 per QALY gain, SNS has a 55% chance of
being the optimal strategy (and, therefore, FENIX has a 45% chance of being the optimal strategy).
Table 28 includes a range of deterministic sensitivity analyses. The analyses include using complete-
case costs and QALYs from the trial, changing the year at which battery replacement is conducted in
the SNS group, changes to health state costs and utilities, and assuming equivalent effectiveness across
interventions at 18 months. In most analyses, the decision is unchanged (i.e. SNS remains the optimal
strategy). A significant drop in the utility estimates for those without a device in situ substantially reduces




































FIGURE 7 Cost-effectiveness acceptability curve.
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FIGURE 8 Markov model traces: (a) SNS; and (b) FENIX.











FENIX £18,657 10.12 £183,806
SNS £19,972 10.33 £1315 0.20 £6508 £186,531
Probabilistic
FENIX £18,668 10.09 £183,130
SNS £19,975 10.32 £1306 0.23 £5694 £186,413
In all cases, we have reversed the incremental value calculation for ease of interpretation. In the alternative format,
FENIX leads to negative costs, QALYs and ICERs, which would denote the money saved per QALY loss.
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FIGURE 10 Cost-effectiveness acceptability curve.
TABLE 28 Deterministic one-way and scenario analyses
Intervention Costs QALYs Incremental cost Incremental QALYs ICER NMB
Base case scenario
FENIX £18,657 10.12 £183,806
SNS £19,972 10.33 £1315 0.20 £6508 £186,531
Complete-case scenario
FENIX £19,855 10.15 £183,189
SNS £21,027 10.35 £1173 0.20 £5973 £185,943
Battery replacement at year 5
FENIX £18,657 10.12 £183,806
SNS £20,681 10.33 £2023 0.21 £9830 £185,899
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FENIX also becomes the optimal strategy (cost saving but marginally less effective) when the proportions
of patients across CCIS percentage improvement and explant groups are assumed to be equivalent at
the trial end.
Table 29 includes the per patient and population EVPI. These values reflect a monetary cost (attaching
a value of £20,000 to a QALY) of the uncertainty in the current decision problem. At the NICE willingness-to-
pay per QALY threshold of £20,000, there was a 55% and a 45% chance that SNS and FENIX, respectively,
were the optimal intervention and, hence, there was significant uncertainty remaining in the decision. Given
the large number of potential intervention recipients, the cost of this uncertainty over 1 year and 10 years is
considerable.The EVPI estimates indicate that further research in this area is warranted to reduce the level
of decision uncertainty.
TABLE 28 Deterministic one-way and scenario analyses (continued )
Intervention Costs QALYs Incremental cost Incremental QALYs ICER NMB
Additional battery replacement at year 14 (only cost implications)
FENIX £18,657 10.12 £183,806
SNS £20,300 10.33 £1643 0.20 £8134 £186,203
50% increase in FI cost after explant (£1264)
FENIX £25,486 10.12 £176,977
SNS £27,555 10.33 £2069 0.20 £10,245 £178,948
Cost of FI assuming 100% use pads, 7.5% use irrigation, 2.5% use anal plug and 7.5% have a stoma (£1895 on average per
year; base case £632)
FENIX £32,303 10.12 £170,160
SNS £34,798 10.33 £2495 0.20 £12,353 £171,705
25% reduction in the utility for patients after device explanted
FENIX £18,657 8.32 £147,792
SNS £20,300 8.43 £1643 0.10 £15,784 £148,230
50% reduction in the utility for patients after device explanted
FENIX £18,657 6.52 £111,777
SNS £20,300 6.53 £1643 0.01 £265,313 £110,258
FENIX proportion of patients at end of trial equal to SNS
FENIX £18,904 10.32 £187,542
SNS £20,300 10.33 £1397 0.00 £489,114 £186,203
In all cases, we have reversed the incremental value calculation for ease of interpretation. In the alternative format,
FENIX leads to negative costs, QALYs and ICERs, which would denote the money saved per QALY loss.
TABLE 29 Expected value of perfect information (λ= £20,000)
Parameter Value
Per person EVPI £9630
FI annual incidence 13,126
Total population EVPI at 1 year £126,403,677
Total population EVPI at 10 years £1,264,036,774
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Although the SaFaRI trial failed to recruit the planned 350 participants, it is nevertheless thelargest reported evaluation of the MAS (FENIX) device to our knowledge, providing important
information about circumanal implants to augment anal sphincter function and treat FI. Despite
initial encouraging results in small, single-centre studies, which provided the rationale for this larger
randomised clinical trial, the FENIX device was taken off the market in 2017, when the manufacturing
company (Torax Medical, Minneapolis, MN, USA) was purchased by Johnson and Johnson (New
Brunswick, NJ, USA). The decision to discontinue marketing the FENIX device was said to be strategic,
with Johnson and Johnson continuing to market a related device (LINX®) for the treatment of gastro-
oesophageal reflux.
The SaFaRI trial involved 18 pelvic floor centres, with colorectal surgeons from across the UK who
were members of the Association of Coloproctology of Great Britain and Ireland. The majority of cases
were recruited from a single site (St James’s University Hospital, Leeds), which may have an impact
on the generalisability of the results. In mitigation, strenuous attempts were made to standardise
the technique for MAS implantation with preceptorship of training cases performed to manufacturer
guidelines. The technique for SNS implantation was left to individual surgeons to reflect normal practice.
The study population was typical of that suffering from moderate to severe FI, with the majority of
participants being female and a median age of 59.0 years. In accordance with the known aetiology
of FI, previous obstetric injury accounted for the majority of cases, with mixed passive and urge
incontinence being the predominant symptomatology.
Previous studies of SNS have reported outcomes at time points relative to the patient’s operation (either
temporary or permanent SNS), which makes comparison with the results of the SaFaRI trial difficult. In
the SaFaRI trial, the patient outcomes were measured at time points relative to randomisation (i.e. from
the key decision-making event, rather than from operation). This approach evaluates the effect of the
decision of which intervention to give the patient. It provides data that is more informative to clinicians
and patients when weighing up the risks and benefits of surgical treatment for FI, and is preferred over
the previously reported per-protocol analyses.
The 18-month follow-up post randomisation was chosen with the expectation that definitive device
operations (FENIX and permanent SNS) would occur within around 6 months post randomisation, giving
patients around 12 months’ follow-up post operation. The median time of 57.0 days from randomisation to
implantation of a FENIX device probably conforms to normal NHS practice. The median time of 371 days
from randomisation to implantation of a permanent SNS device, although longer than our a priori
expectation, might not be unusual in the NHS, where there are surgical capacity issues and benign
conditions tend to be given low priority. This delay in undertaking permanent SNS implantation had a
bearing on the number of patients who had a device in situ and had completed 18 months’ follow-up at
the time of stopping the study.
In total, five (10%) participants withdrew from surgery in the FENIX group and did not undergo device
implantation. This compared with five (10.2%) participants not receiving a temporary SNS device, four
(8.2%) participants not undergoing implantation, and a further 12 (24.5%) participants not proceeding
from a temporary device to a permanent device owing to lack of efficacy. This gives an intention-to-
treat figure of 57.1% and a per-protocol figure of 62.2% of patients progressing to a permanent
implant, which is generally in keeping with the literature. However, the success rate at 18 months, as
judged by the intention-to-treat analysis, was very low at 8.2%. Even on a per-protocol basis, of the
28 participants who received a permanent SNS implant, only four (14.3%) reported a successful outcome
with the device in situ and sustained benefit at 18 months’ follow-up. This contrasts with the literature,
which generally reports success rates between 50 and 70%. In a long-term analysis of 407 patients
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undergoing SNS, Altomare et al.44 reported progression from temporary to permanent implant in 66.8%
of patients. At a median of 84 months’ follow-up, success was maintained in 71.3% of patients in
per-protocol analysis and 47.7% on intention-to-treat analysis.44 Similar results were reported in the
systematic review published by Thin et al.,45 with the median success rate of SNS, on intention to treat,
being 63%, 58% and 54% on short-, medium-, and long-term follow-up, respectively.
The reason for the large discrepancy between the success rates observed in SaFaRI and those reported
in the literature is not clear. One possible explanation is the rigour of data collection within the context
of a RCT, giving a more accurate reflection of true success. It is possible that the large number of sites
participating in SaFaRI, compared with the single-centre studies reported in the literature, may have
captured data from widely different practices, although all participating surgeons were experienced with
the SNS technique prior to participation in the study. The proportion of patients who progressed from the
temporary SNS device to the permanent SNS device is similar to the proportions seen in the literature. The
discrepancy is seen in the number of successes in the patients who received the permanent SNS implant.
Four patients did not receive the permanent SNS device before 18 months post randomisation, and so were
classed as ‘failures’ according to the definition of the primary end point, which may explain some of the
discrepancy. Most other studies have used a 50% reduction in the number of FI episodes per week as
their end point rather than 50% improvement in CCIS, which was used in SaFaRI. This could also explain
some of the discrepancy between the results of SaFaRI and those reported in the literature.
A similar low success rate was observed with the FENIX device, with only six (13.3%) successes out of
45 participants who underwent device implantation. Again, this is much lower than in the reported
literature. Pakravan et al.46 reported a success rate of 76% in 18 patients undergoing FENIX implantation,
defined as a ≥ 50% reduction in FI rates per week, with no explants. In a longer-term study, Sugrue
et al.47 reported on 37 FENIX patients with a median follow-up of 5 years. Therapeutic success rates at
1, 3 and 5 years were 63%, 66% and 53%, respectively. The lower success rate of the FENIX device in
SaFaRI appears to have been because of a higher proportion of patients not experiencing an improvement
in CCIS (36.6% of the 41 patients with complete data) and a higher explant rate (33% of the 45 implants).
Both the FENIX and the SNS interventions proved to be relatively safe, with few intraoperative
complications. However, the postoperative complications were high, particularly in the FENIX group
(73.3%), with participants receiving the FENIX intervention being 11 times more likely to suffer a
postoperative complication, a difference that did not appear to be related to the effect of the
operating surgeon. Notably, the most commonly reported complication in the FENIX group was
worsening symptoms of obstructed defaecation (20.5%). Recommendation was made that patients
should have an ODS of < 8 for entry to SaFaRI. The baseline characteristics for the whole group
showed a median ODS of 7.0 (range 2.0–18.0), and perhaps with more stringent inclusion criteria this
complication would have been reduced. However, there was no difference in ODS between the two
treatment arms and having a device in situ did not have a significant effect on ODS. It is possible that
patients in the FENIX group were more likely to attribute any obstructed defaecation symptoms to
the implanted device. The high complication rate with the FENIX device is mirrored in the literature.
Sugrue et al.47 reported 30 adverse events in 35 patients undergoing FENIX implantation, with the
most common being defaecatory dysfunction (20%), followed by pain (14%), erosion (11%) and
infection (11%).47 In Pakravan et al.’s46 smaller study of 18 patients, the most common complication was
postoperative pain (29%). The FENIX explant rate observed in SaFaRI was much higher than previously
reported, with 15 out of the 45 implants (33.3%) being explanted by the 18-month time point, with the
majority explanted within 6 months. Similarly, the complication rate in the SNS group (22.5%) was
higher than might be expected from the literature. This might be a result of rigorous data collection
within a randomised trial and the fact that all possible complications were recorded, which is not
always the case in single-centre cohort studies.
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For those patients who retained a device, there was a statistically significant benefit in terms of reduction
in CCIS, but there was no difference between the treatment groups, with the effect sustained throughout
follow-up. This benefit was independent of baseline CCIS. Likewise, for patients who retained a device
there was a sustained improvement in QoL as calculated by the EQ-5D-5L score, but not the VAS, with
no difference between the treatment groups. The FIQoL showed a similar pattern, with improvement
in all QoL domains if the device remained in situ. Both Pakravan et al.46 and Sugrue et al.47 reported
improvement in FIQoL scores across all domains following FENIX implantation, although several studies
attest to the benefit of SNS in improving FIQoL.48–50 The benefit from a functioning FENIX or SNS device
appears to be more on physical than mental abilities, as judged by the SF-12 v2 analysis.
An economic evaluation of FENIX compared with SNS was undertaken from the perspective of the
social and health-care provider. Estimates of cost-effectiveness were produced over the trial period
and over a lifetime horizon using a de novo decision model.
At the end of the trial, slightly lower costs were observed in the SNS group despite the fact that
intervention costs were significantly higher in this group. There were notably higher secondary care
costs in the FENIX arm, which appears to be driven by the complication and other surgery rates.
There were also higher (self-reported) primary care costs in the FENIX arm.
There was a small QALY intervention differential at 18 months in favour of FENIX; however, at 18 months,
the ICERs for FENIX compared with SNS were > £20,000, except for analyses using cross-walking to
EQ-5D-3L. The patient proportions across health state groups at the end of the trial (feeding into
the decision model) slightly favoured SNS, despite this group having a higher proportion of patients
without a device in situ. The trial results were highly sensitive to choice of estimation model and utility
derivation strategy.
The lifetime expected costs and QALYs generated by the decision model were a reversal of those
observed at 18 months; that is, in the long term, FENIX was less costly but also less effective. The base
case analysis still indicated that FENIX was not cost-effective compared with SNS and that the latter
strategy was optimal. This finding held in most sensitivity analyses, except where there were significant
reductions in the explanted group QoL and where the effectiveness at trial end was assumed to be
equivalent between arms.
Our model estimated lifetime costs similar to the 5 years’ costs (€22,150) estimated elsewhere for SNS,13
and it is unclear what drives this disparity. Another evaluation of SNS also used a 5-year time horizon32
yielding similar 5-year SNS costs (£13,829–19,153). There are few other published economic evaluations
in this population37,51 and none comparing SNS with FENIX. One abstract reports this direct comparison
over 1 year and finds similar results to ours (FENIX being more effective and more costly) over this
period, but finding an ICER of < £20,000.52
Limitations
The SaFaRI study was limited by the small number of patients recruited as a consequence of the
FENIX device being taken off the market less than one-third of the way through the study. Any
conclusions therefore have to be taken with caution, given that the sample size was inadequate to
show a difference between the two treatments. Despite the small numbers, important information has
been gained, particularly relating to the patient pathways, delays in treatment and the complication
profiles of the two treatments.
As expected, given the small sample and loss to follow-up, there is significant uncertainty in the cost-
effectiveness results. The 18 months’ results were influenced by the approach to dealing with missing
data and utility assessment. It is possible that the difference in post-procedure follow-up timing across
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arms may have affected the relative costs and QALYs captured, increasing uncertainty. The longer-term
results were heavily reliant on the effectiveness data from the trial, which are relatively weak. A number
of assumptions were necessary in the decision modelling (not all of which were incorporated in
sensitivity analyses) and these may have a significant impact on the model outputs. A larger sample
size would have permitted greater confidence in the model parameter values generated from the trial
data. More nuanced approaches may also have been enabled (e.g. having differing effectiveness decay
rates for the two interventions). Our analyses were limited to the health-care perspective; taking a
broader view (e.g. including patient out-of-pocket costs) may have affected results, especially if those
without a device in situ covered a proportion of conservative management costs themselves.
Given these factors and the level of uncertainty in the results, it is difficult to commend one
intervention over another on the basis of the evidence presented. The results from the value of
information analysis suggest that further research is warranted.
Future research
Future research might include longer follow-up of SaFaRI participants to ensure accurate capture of
efficacy and explant rates in the longer term. There would be scope for further economic modelling to
include standard (non-operative) care and additional data from other studies, and new devices for FI.
Because SaFaRI was terminated early, as a result of a buyout of the manufacturer, the sample size is
greatly reduced from that originally planned. There is a possible option of undertaking a meta-analysis
of a similar study undertaken in France52 to gain a better understanding of the efficacy and safety of
the FENIX and SNS devices.
DISCUSSION
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Chapter 5 Conclusions
The SaFaRI study suggests that neither FENIX nor SNS is as effective in treating FI of moderate tosevere severity as previously reported in the literature. The FENIX device was associated with a
high postoperative morbidity, including the risk of explantation within the first year. The FENIX device
was withdrawn from the market in 2017 and the results from SaFaRI would not support its reintroduction
in its current form. Similar high rates of complications and explantation have been observed with other
circumanal sphincter augmentation devices, such as the Acticon Neosphincter® (American Medical Systems,
Minneapolis, MN, USA). New strategies are needed for anal sphincter augmentation that avoid the use of
prosthetic implants that can become infected and erode.
Although the results for SNS, as observed in SaFaRI, were disappointing, it remains a recommended
treatment by NICE for patients with moderate to severe FI that is resistant to medical management.
It is unlikely, given its established place in surgical practice, that the use of SNS will decline as a
consequence of SaFaRI. However, more research is required to unravel why the pathways for SNS
are so inefficient, with patients suffering long waiting times for treatment of a disabling condition.
The technique for SNS continues to evolve and new devices are coming to the market. The NIHR
SUBSoNIC study is currently recruiting and investigating the efficacy and mechanism of subsensory
(optimised) neuromodulation in adults with FI.53 It will be interesting to see how the outcomes of this
study will compare with those of SaFaRI.
Use of our health economics model to incorporate synthesised evidence from other studies and
explore other scenarios (e.g. new devices with longer battery lives) may be informative in the future.
Previous research indicated that SNS was only marginally cost-effective compared with conservative
management12 and perhaps the latter strategy could be included in a wider evaluation.
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Appendix 1
Summaries of components of the ‘success’ end point at 6, 12 and 18 months
post randomisation
TABLE 30 Success defined by device in use and ≥ 50% improvement in CCIS
Success FENIX MSA, n (%) SNS, n (%) Total, n (%)
6 months post randomisation
Unsuccessful 33 (86.8) 18 (100.0) 51 (91.1)
Successful 5 (13.2) 0 (0.0) 5 (8.9)
Total 38 (100) 18 (100) 56 (100)
12 months post randomisation
Unsuccessful 35 (87.5) 26 (96.3) 61 (91.0)
Successful 5 (12.5) 1 (3.7) 6 (9.0)
Total 40 (100) 27 (100) 67 (100)
18 months post randomisation
Unsuccessful 35 (85.4) 35 (89.7) 70 (87.5)
Successful 6 (14.6) 4 (10.3) 10 (12.5)
Total 41 (100) 39 (100) 80 (100)
TABLE 31 Success defined by ≥ 50% improvement in CCIS
≥ 50% improvement in CCIS? FENIX MSA, n (%) SNS, n (%) Total, n (%)
6 months post randomisation
No 33 (86.8) 18 (100.0) 51 (91.1)
Yes 5 (13.2) 0 (0.0) 5 (8.9)
Total 38 (100) 18 (100) 56 (100)
12 months post randomisation
No 35 (87.5) 25 (92.6) 60 (89.6)
Yes 5 (12.5) 2 (7.4) 7 (10.4)
Total 40 (100) 27 (100) 67 (100)
18 months post randomisation
No 34 (82.9) 34 (87.2) 68 (85.0)
Yes 7 (17.1) 5 (12.8) 12 (15.0)
Total 41 (100) 39 (100) 80 (100)
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TABLE 32 Success defined by device in use
Device in use? FENIX MSA, n (%) SNS, n (%) Total, n (%)
6 months post randomisation
Yes 27 (71.1) 5 (27.8) 32 (57.1)
No 11 (28.9) 13 (72.2) 24 (42.9)
Total 38 (100) 18 (100) 56 (100)
12 months post randomisation
Yes 25 (62.5) 11 (40.7) 36 (53.7)
No 15 (37.5) 16 (59.3) 31 (46.3)
Total 40 (100) 27 (100) 67 (100)
18 months post randomisation
Yes 21 (51.2) 16 (41.0) 37 (46.3)
No 20 (48.8) 23 (59.0) 43 (53.8)
Total 41 (100) 39 (100) 80 (100)
TABLE 33 Cross-tabulation of the components
Improvement in continence
Device in use?
No, n (%) Yes, n (%) Total, n (%)
FENIX MSA (6 months post randomisation)
≥ 50% improvement in CCIS?
No 11 (100.0) 22 (81.5) 33 (86.8)
Yes 0 (0.0) 5 (18.5) 5 (13.2)
Total 11 (100) 27 (100) 38 (100)
SNS (6 months post randomisation)
≥ 50% improvement in CCIS?
No 13 (100.0) 5 (100.0) 18 (100.0)
Yes 0 (0.0) 0 (0.0) 0 (0.0)
Total 13 (100) 5 (100) 18 (100)
FENIX MSA (12 months post randomisation)
≥ 50% improvement in CCIS?
No 15 (100.0) 20 (80.0) 35 (87.5)
Yes 0 (0.0) 5 (20.0) 5 (12.5)
Total 15 (100) 25 (100) 40 (100)
SNS (12 months post randomisation)
≥ 50% improvement in CCIS?
No 15 (93.8) 10 (90.9) 25 (92.6)
Yes 1 (6.3) 1 (9.1) 2 (7.4)
Total 16 (100) 11 (100) 27 (100)
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Exploratory analyses: additional covariates
Cleveland Clinic Incontinence Score
There were 96 out of 99 (97%) patients included in the analysis, meaning that they each provided their
CCIS at least once at one of the baseline, 6-, 12- or 18-month time points.
The CCIS data were modelled using a three-level multilevel model, with time points clustered within
patients and patients clustered within surgeons. The estimates of the fixed effects can be seen in
Table 34. The random effect caused by surgeon was 0 and the random effect caused by within-patient
measurements was 5.93 (SE 1.26). The residual of the random effects was 7.13 (SE 0.71).
TABLE 33 Cross-tabulation of the components (continued )
Improvement in continence
Device in use?
No, n (%) Yes, n (%) Total, n (%)
FENIX MSA (18 months post randomisation)
CCIS improvement?
No 19 (95.0) 15 (71.4) 34 (82.9)
Yes 1 (5.0) 6 (28.6) 7 (17.1)
Total 20 (100) 21 (100) 41 (100)
SNS (18 months post randomisation)
CCIS improvement?
No 22 (95.7) 12 (75.0) 34 (87.2)
Yes 1 (4.3) 4 (25.0) 5 (12.8)
Total 23 (100) 16 (100) 39 (100)
TABLE 34 Fixed effects
Covariate Estimate SE p-value 95% CI
Intercept 11.1227 1.1579 < 0.0001 8.6546 to 13.5907
FENIX MSA vs. SNS 0.1052 0.6643 0.8744 –1.2048 to 1.4152
Male vs. female 1.0012 1.6859 0.5533 –2.3234 to 4.3258
Baseline CCIS > 10 points (moderate to
severe) vs. ≤ 10 points (mild to moderate)
3.4638 1.1137 0.0021 1.2677 to 5.6600
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
0.5030 0.6384 0.4316 –0.7547 to 1.7624
Anal sphincter defect > 90° to < 180°
vs. no anal sphincter defect
0.7415 1.1433 0.5174 –0.7558 to 1.7619
Time (months) –0.07833 0.07518 0.2987 –1.5131 to 2.9961
Device in use –3.0386 0.7209 < 0.0001 –4.4601 to –1.6171
Time and baseline CCIS interaction
(CCIS > 10 points vs. CCIS ≤ 10 points)
0.03473 0.07793 0.6564 –0.1189 to 0.1884
Device in use and treatment interaction –0.1304 0.8309 0.8755 –1.7688 to 1.5080
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Patients who were randomised to the FENIX MSA arm have a baseline CCIS 0.11 points lower than
patients randomised to SNS; however, this result is not statistically significant (p = 0.9). Patients having
a device in use reduces the CCIS by 3.04 points, a result that is statistically significant (p < 0.0001);
however, the interaction term is not statistically significant (p = 0.9). The estimated change in CCIS over
time is small; there is a reduction of 0.078 points per month on average, although the CI around this
estimate is large owing to the small number of patients. The baseline CCIS (≤ 10 points or > 10 points)
has a significant effect on the CCIS (p = 0.005), as would be expected due to them using the same
measure; however, the interaction between baseline CCIS and time was not significant (p = 0.8).
The results of the model can be seen in Figure 11. This figure shows the difference between two
identical patients, with the only difference being the randomised treatment, and assuming they
received the device after 6 months and it remained in use at 12 and 18 months post randomisation.
EuroQol-5 Dimensions, five-level version
There were 96 out of 99 (97%) patients included in the analysis, meaning that 96 patients provided a
score at least once at one of the baseline, 6-, 12- or 18-month time points.
The EQ-5D-5L score was modelled using a three-level multilevel model, with time points clustered
within patients and patients clustered within surgeons. The fixed effects of the model are presented in
Table 35. The random effect caused by surgeon was 0.00 (SE 0.003) and the random effect caused by
within-patient measurements was 0.04 (SE 0.007). The residual of the random effects was 0.03 (SE 0.003).
The model did not show a significant difference in the score between treatment arms (p = 0.76) or
over time (p = 0.18). The device being in use has a statistically significant difference of 0.13 (p = 0.004),
meaning that patients with their device in use have an EQ-5D-5L score 0.13 points higher than patients
without the device in use, and this difference is the same for patients randomised to both treatment arms,
as can be seen by the non-significance of the device in use and treatment interaction (p = 0.2). There is
no indication that there is a clustering effect caused by the randomising surgeon.
The results of the model can be seen in Figure 12, which presents estimates and 95% CIs for the
EQ-5D-5L score at 6, 12 and 18 months post randomisation for two patients who are identical except
for their randomised treatment, and assuming that they received the device after 6 months and it

























FIGURE 11 Cleveland Clinic Incontinence Score model results.
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TABLE 35 Fixed effects of EQ-5D-5L model
Covariate Estimate SE p-value 95% CI
EQ-5D-5L score model
Intercept 0.7408 0.07531 < 0.0001 0.5803 to 0.9013
FENIX MSA vs. SNS 0.01453 0.04771 0.7610 –0.07953 to 0.1086
Male vs. female 0.03300 0.1249 0.7918 –0.2132 to 0.2792
Baseline CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–0.1180 0.06974 0.0922 –0.2555 to 0.01950
Anal sphincter defect ≤ 90° vs. no anal sphincter defect 0.01844 0.04755 0.6986 –0.07530 to 0.1122
Anal sphincter defect > 90° to < 180° vs. no anal
sphincter defect
–0.02196 0.08345 0.7927 –0.1865 to 0.1426
Time (months) –0.00250 0.001854 0.1785 –0.00616 to 0.001152
Device in use 0.1300 0.04494 0.0042 0.04144 to 0.2186
Device in use and treatment interaction –0.06466 0.05166 0.2121 –0.1665 to 0.03718
EQ-5D-5L VAS model
Intercept 81.1491 6.4029 < 0.0001 67.5016 to 94.7967
FENIX MSA vs. SNS –4.3211 3.7654 0.2525 –11.7444 to 3.1022
Male vs. female –4.9907 9.9532 0.6166 –24.6127 to 14.6313
CCIS > 10 points (moderate to severe) vs. ≤ 10 points
(mild to moderate)
–14.1538 6.1549 0.0225 –26.2878 to –2.0199
Anal sphincter defect ≤ 90° vs. no anal sphincter defect 1.4308 3.7453 0.7028 –5.9529 to 8.8144
Anal sphincter defect > 90° to < 180° vs. no anal
sphincter defect
2.7676 6.7168 0.6807 –10.4741 to 16.0093
Time (months) –0.02979 0.3702 0.9359 –0.7596 to 0.7001
Device in use 5.8162 3.5563 0.1035 –1.1947 to 12.8272
Time and CCIS interaction (CCIS ≤ 10 points vs. CCIS
> 10 points)
0.04212 0.3831 0.9126 –0.7131 to 0.7973






























FIGURE 12 EQ-5D score model results.
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The EQ-5D-5L questionnaire also records the respondent’s self-rated health on a vertical VAS ranging
from 0–100, in which higher numbers indicate better health.
A total of 97 out of 99 (98%) patients were included in the VAS analysis, meaning that they provided a
VAS score at least at one time point.
The VAS was modelled using a three-level multilevel model with time points clustered within patients and
patients clustered within surgeons. The fixed effects of the model can be seen in Table 35. The random
effect caused by surgeon was 0 and the random effect caused by within-patient measurements was 233.05
(SE 44.06). The residual of the random effects was 169.71 (SE 16.62). The randomised treatment has no
significant effect on the VAS score (p = 0.25) and there is no significant difference over time between the
two treatment arms (p = 0.9). The baseline CCIS minimisation factor has a statistically significant effect
(p = 0.023); however, the effect over time is not significant, meaning that the baseline VAS score is higher
for patients who have a baseline CCIS ≤ 10 points, but the VAS score changes at the same rate for patients
with a baseline CCIS ≤ 10 points and > 10 points. The device being in use does not have a significant effect
on the VAS score (p = 0.1) and the effect is not significantly different between the treatment arms (p= 0.3)
There is no indication of a clustering effect caused by the randomising surgeon.
The results of the model can be seen in Figure 13, which presents estimates and 95% CIs for the
EQ-5D-5L VAS score at 6, 12 and 18 months post randomisation for two patients who are identical
except for their randomised treatment, and assuming that they received the device after 6 months and
it remained in use at 12 and 18 months post randomisation.
The model diagnostics can be seen in Figures 14 and 15.
Faecal incontinence quality of life
The results of the models fitted are summarised in Table 36. None of the domains shows any significant
difference between the treatment arms. All of the domains show a statistically significant improvement
in FIQoL when the device is in use and there is no significant difference in the improvement between



























FIGURE 13 EQ-5D VAS model results.
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FIGURE 14 Model residuals for EQ-5D-5L score. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals



















































FIGURE 15 Model residuals for EQ-5D VAS. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals
with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of the raw residuals.
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TABLE 36 Lifestyle domain model results: fixed effects
Covariate Estimate SE p-value 95% CI
Lifestyle domain
Intercept 2.9449 0.3039 < 0.0001 2.2971 to 3.5927
FENIX MSA vs. SNS 0.01600 0.1824 0.9302 –0.3437 to 0.3757
Male vs. female –0.4174 0.4905 0.3958 –1.3850 to 0.5501
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–0.8378 0.2893 0.0042 –1.4085 to –0.2672
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
–0.03691 0.1849 0.8420 –0.4017 to 0.3278
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–0.01219 0.3427 0.9717 –0.6882 to 0.6639
Time (months) 0.000148 0.000462 0.7491 –0.00076 to 0.001059
Device in use 0.4124 0.1526 0.0075 0.1113 to 0.7135
Time and CCIS interaction (CCIS
≤ 10 points vs. CCIS > 10 points)
0.000119 0.000482 0.8051 –0.00083 to 0.001070
Device in use and treatment interaction 0.06514 0.1701 0.7022 –0.2705 to 0.4007
Coping domain
Intercept 2.0434 0.2566 < 0.0001 1.4931 to 2.5937
FENIX MSA vs. SNS 0.004001 0.1468 0.9783 –0.2862 to 0.2942
Male vs. female 0.1544 0.3750 0.6811 –0.5869 to 0.8958
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–0.6468 0.2415 0.0083 –1.1242 to –0.1694
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
0.03141 0.1497 0.8341 –0.2645 to 0.3273
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–0.03069 0.2533 0.9037 –0.5314 to 0.4700
Time (months) 0.000235 0.000544 0.6666 –0.00084 to 0.001311
Device in use 0.5340 0.1441 0.0003 0.2493 to 0.8188
Time and CCIS interaction (CCIS
≤ 10 points vs. CCIS > 10 points)
0.000168 0.000568 0.7685 –0.00096 to 0.001291
Device in use and treatment interaction 0.2217 0.1693 0.1926 –0.1131 to 0.5564
Depression domain
Intercept 3.2273 0.3340 <0.0001 2.5109 to 3.9436
FENIX MSA vs. SNS 0.05262 0.1948 0.7874 –0.3323 to 0.4376
Male vs. female 0.01222 0.4939 0.9803 –0.9638 to 0.9882
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–0.8544 0.3116 0.0069 –1.4701 to –0.2387
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
–0.1388 0.2016 0.4924 –0.5372 to 0.2597
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–0.1428 0.3481 0.6823 –0.8307 to 0.5452
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In the lifestyle domain, the random effect caused by surgeon was 0 and the random effect
caused by within-patient measurements was 0.61 (SE 0.10). The residual of the random effects
was 0.25 (SE 0.03).
In the coping domain, the random effect caused by surgeon was 0 and the random effect
caused by within-patient measurements was 0.32 (SE 0.06). The residual of the random effects
was 0.22 (SE 0.03).
In the depression domain, the random effect caused by surgeon was 0 and the random effect
caused by within-patient measurements was 0.60 (SE 0.11). The residual of the random effects
was 0.27 (SE 0.03).
In the embarrassment domain, the random effect caused by surgeon was 0 and the random effect
caused by within-patient measurements was 0.38 (SE 0.07). The residual of the random effects
was 0.21 (SE 0.02).
The results of the models can be seen in Figures 16–19, which present estimates and 95% CIs for each
of the FIQoL domains at 6, 12 and 18 months post randomisation for two patients who are identical
except for their randomised treatment, and assuming that they received the device after 6 months and
it remained in use at 12 and 18 months post randomisation.
The model diagnostics corresponding to models of the lifestyle, coping, depression and embarrassment
domains of the FIQoL can be seen in Figures 20–23, respectively.
TABLE 36 Lifestyle domain model results: fixed effects (continued )
Covariate Estimate SE p-value 95% CI
Time (months) –6.32E-6 0.000557 0.9910 –0.00111 to 0.001095
Device in use 0.4244 0.1617 0.0096 0.1048 to 0.7439
Time and CCIS interaction (CCIS
≤ 10 points vs. CCIS > 10 points)
0.000017 0.000581 0.9772 –0.00113 to 0.001165
Device in use and treatment interaction –0.04992 0.1872 0.7901 –0.4199 to 0.3201
Embarrassment domain
Intercept 2.3581 0.2489 < 0.0001 1.8276 to 2.8886
FENIX MSA vs. SNS –0.01209 0.1465 0.9343 –0.3008 to 0.2766
Male vs. female 0.3032 0.3921 0.4402 –0.4697 to 1.0761
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–0.7196 0.2382 0.0067 –1.1891 to –0.2500
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
0.003584 0.1475 0.9806 –0.2873 to 0.2945
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–0.2464 0.2634 0.3505 –0.7656 to 0.2727
Time (months) 0.000492 0.000441 0.2662 –0.00038 to 0.001361
Device in use 0.3192 0.1252 0.0115 0.07244 to 0.5659
Time and CCIS interaction (CCIS
≤ 10 points vs. CCIS > 10 points)
–0.00038 0.000457 0.4107 –0.00128 to 0.000525
Device in use and treatment interaction 0.2677 0.1433 0.0632 –0.01482 to 0.5503
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FIGURE 18 The FIQoL depression model results.
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FIGURE 20 Model residuals for FIQoL: lifestyle. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals
with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of the raw residuals.
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FIGURE 21 Model residuals for FIQoL: coping. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals
















































FIGURE 22 Model residuals for FIQoL: depression. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw
residuals with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of the
raw residuals.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
Obstructed Defecation Score
The results of the model fitted to the ODS data can be seen in Table 37. There is no significant
difference in the ODS between the two treatment arms (p = 0.64). Whether or not the patient has the
device in use does not have a statistically significant difference on the ODS (p = 0.58).
The random effect caused by surgeon was 0 and the random effect caused by within patient











































FIGURE 23 Model residuals for FIQoL: embarrassment. (a) Raw residuals vs. linear predictor value; (b) histogram of the
raw residuals with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of
the raw residuals.
TABLE 37 Obstructed Defecation Score model results: fixed effects
Covariate Estimate SE p-value 95% CI
Intercept 5.2302 1.2865 0.0010 2.4882 to 7.9723
FENIX MSA vs. SNS 1.1086 0.7205 0.1256 –0.3130 to 2.5301
Male vs. female 0.3308 2.0760 0.8736 –3.7648 to 4.4264
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
1.8101 1.2449 0.1476 –0.6458 to 4.2661
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
0.5190 0.7554 0.4929 –0.9713 to 2.0092
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–1.0357 1.3198 0.4336 –3.6394 to 1.5680
Time (months) –0.00207 0.002504 0.4098 –0.00701 to 0.002871
Device in use 0.3027 0.5458 0.5798 –0.7740 to 1.3795
Time and CCIS interaction (CCIS
≤ 10 points vs. CCIS > 10 points)
0.002587 0.002631 0.3267 –0.00260 to 0.007777
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The results of the model can be seen in Figure 24, which presents estimates and 95% CIs for each of
the ODSs at 6, 12 and 18 months post randomisation for two patients who are identical except for
their randomised treatment, and assuming that they received the device after 6 months and it
remained in use at 12 and 18 months post randomisation.



















































FIGURE 25 Model residuals for ODS. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals with




















FIGURE 24 Obstructed Defecation Score model results.
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Short Form questionnaire-12 items version 2
The fixed effects of the multilevel model fitted to the data can be seen in Table 38. Both models show
that there is no difference between the PCS/MCS for patients randomised to the two treatment arms.
The PCS model shows a statistically significant increase in score of 3.07 if the patient has the device
in use (p = 0.04), and this difference is not significantly different for the treatment arms (p = 0.6).
The MCS model does not show any statistically significant difference in the score if the patient has
the device in use. The MCS model shows a significant difference between the scores for patients who
have mild to moderate CCIS versus moderate to severe CCIS (p = 0.004); however, this effect is not
significantly different over time (p = 0.48).
For the PCS model, the random effect caused by surgeon was 2.45 (SE 5.84) and the random effect
caused by within-patient measurements was 61.14 (SE 11.45). The residual of the random effects was
30.52 (SE 2.93).
TABLE 38 Fixed effect estimates of PCS model
Covariate Estimate SE p-value 95% CI
PCS model
Intercept 51.5532 3.0005 < 0.0001 45.1578 to 57.9486
FENIX MSA vs. SNS –1.8281 1.8383 0.3211 –5.4514 to 1.7953
Male vs. female 1.6534 5.0070 0.7416 –8.2158 to 11.5225
CCIS > 10 points (moderate to severe) vs.
≤ 10 points (mild to moderate)
–4.8303 2.7803 0.0838 –10.3104 to 0.6498
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
–0.7844 1.8763 0.6763 –4.4827 to 2.9139
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
–1.4812 3.3644 0.6602 –8.1126 to 5.1502
Time (months) –0.1045 0.05933 0.0797 –0.2214 to 0.01247
Device in Use 3.0712 1.4691 0.0377 0.1756 to 5.9668
Device in use and treatment interaction –0.9068 1.7147 0.5975 –4.2866 to 2.4729
MCS model
Intercept 51.4858 3.7708 < 0.0001 43.4485 to 59.5231
FENIX MSA vs. SNS –1.6192 2.1049 0.4426 –5.7680 to 2.5295
Male vs. female –1.5167 5.8981 0.7973 –13.1419 to 10.1085
Baseline CCIS > 10 points (moderate to
severe) vs. ≤ 10 points (mild to moderate)
–10.7417 3.6346 0.0035 –17.9056 to –3.5778
Anal sphincter defect ≤ 90° vs. no anal
sphincter defect
–0.4134 2.2128 0.8520 –4.7749 to 3.9481
Anal sphincter defect > 90° to < 180° vs.
no anal sphincter defect
2.1652 3.9816 0.5871 –5.6826 to 10.0130
Time (months) –0.1289 0.2084 0.5368 –0.5397 to 0.2818
Device in use 2.4745 1.3824 0.0749 –0.2503 to 5.1993
Time and baseline CCIS interaction 0.1546 0.2168 0.4764 –0.2726 to 0.5819
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For the PCS model, the random effect caused by surgeon was 0 and the random effect caused
by within-patient measurements was 82.30 (SE 15.16). The residual of the random effects was
58.73 (SE 5.62).
The results of the models can be seen in Figures 26 and 27, which present estimates and 95% CIs for
each of the PCS and MCS components of the SF-12 at 6, 12 and 18 months post randomisation for
two patients who are identical except for their randomised treatment, and assuming that they received
the device after 6 months and it remained in use at 12 and 18 months post randomisation.




















































FIGURE 27 Mental Component Summary model results.
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FIGURE 28 Model residuals for SF-12: PCS. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals



















































FIGURE 29 Model residuals for SF-12: MCS. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw residuals
with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of the raw residuals.
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Model diagnostics
The observations that lie furthest from the line are those patients who have a higher probability of a
successful outcome owing to the stratification factors entered at randomisation.
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FIGURE 31 Delta-betas: primary end point.
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The observations with the greatest delta-betas are FENIX patients who did not have a complication,
where the operation was performed by a surgeon that had a slightly higher probability of a
complication occurring.
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FIGURE 32 Empirical probability plot: postoperative complications.


























FIGURE 33 Delta-betas: postoperative complications.
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FIGURE 34 Model residuals for CCIS end point. (a) Raw residuals vs. linear predictor value; (b) histogram of the raw
residuals with normal density overlay for reference; (c) normal Q-Q plot of the raw residuals; and (d) box plot of the
raw residuals.








Cardiorespiratory: serious £1056 Non-elective short stay (DZ19 K): other respiratory
disorders with single intervention, with CC score 0–4
(NHS Reference Costs 2017–201833)
N/A
Urinary retention: serious £359 Non-elective short stay (LB16 K): urinary incontinence
or other urinary problems, without interventions, with
CC score 0–1 (NHS Reference Costs 2017–201833)
N/A
Neurological pain: serious £358 Non-elective short stay (WH08B): unspecified pain with




£1069 Non-elective short stay (FD03E): gastrointestinal
bleed with single intervention, with CC score 0–4
(NHS Reference Costs 2017–201833)
N/A
Wound infection: serious £967 Non-elective short stay (WH07D): infection or other
complications of procedures, with single interventions,
with CC score 0–1 (NHS Reference Costs 2017–201833)
N/A
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prices) Source and assumptions
Inflated
from year
Implant infection: serious £967 Non-elective short stay (WH07D): infection or other
complications of procedures, with single interventions,
with CC score 0–1 (NHS Reference Costs 2017–201833)
N/A
Lead migration/fragmentation:
serious or not serious
£1100 Minor anal procedures, ≥ 19 years, day case (FF42 A)
(NHS Reference Costs 2017–201833)
N/A
Pain at battery site (permanent
SNS) due to non-infective cause
(e.g. battery rotation): serious or
not serious
£1100 Minor anal procedures, ≥ 19 years, day case (FF42 A)
(NHS Reference Costs 2017–201833)
N/A
Lack or loss of efficiency: serious
or not serious





£585 Minimal anal procedure, day case (FF43Z)
(NHS Reference Costs 2017–201833)
N/A
Device failure/separation:
serious or not serious
£1100 Minor Anal Procedures, ≥ 19 years, day case (FF42 A)
(NHS Reference Costs 2017–201833)
N/A
Device erosion: serious or not
serious
£1819 Assume explant occurs and same cost as insertion:
insertion of neurostimulator for treatment of faecal




serious or not serious
£1819 Assume explant occurs and same cost as insertion:
insertion of neurostimulator for treatment of faecal





£585 Minimal anal procedure, day case (FF43Z)
(NHS Reference Costs 2017–201833)
N/A
Other serious complications
Wound still not healed following
explant, fistula
£967 Non-elective short stay (WH07D): infection or other
complications of procedures, with single interventions,
with CC score 0–1 (NHS Reference Costs 2017–201833)
N/A
Wound dehiscence £967 Non-elective short stay (WH07D): infection or other
complications of procedures, with single interventions,
with CC score 0–1 (NHS Reference Costs 2017–201833)
N/A
Covering stoma £1093 Minor anal procedures, ≥ 19 years, non-elective short
stay (FF42 A) (NHS Reference Costs 2017–201833)
N/A
Presented with constipation £585 Minimal anal procedure, day case (FF43Z)
(NHS Reference Costs 2017–201833)
N/A
All non-serious complications (listed and other)
All other non-serious
complications
£105 Colorectal surgery, consultant-led, non-admitted face-
to-face attendance, follow-up (WF01 A) (NHS Reference
Costs 2017–201833)
N/A
CC, complication and comorbidity; N/A, not applicable.
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Explant of device: temporary or
permanent – SNS
£1819 Insertion of neurostimulator for treatment of faecal
incontinence, day case (FF47Z) (NHS Reference Costs
2017–201833)
N/A
Explant of device: temporary or
permanent – FENIX
£1819 Insertion of neurostimulator for treatment of faecal
incontinence, day case (FF47Z) (NHS Reference Costs
2017–201833) (Assumed same as SNS)
N/A
Further surgery and treatments
Biofeedback therapy £345 Initial consultation (£75) and three subsequent
30-minute sessions (£90 each) (BrainTrain UK;
URL: www.braintrainuk.com/about-us/prices/;
last accessed 20 February 2021)
Colostomy formed £13,851 Colectomy
£9218 complex large intestine procedures, ≥ 19 years,
with CC score 3–5 (FF31C) (NHS Reference Costs
2017–201833)
Ileoanal pouch formation/reversal of ileostomy
£4633 major small intestine procedures, ≥ 19 years,
with CC score 0–1 (FF22D) (NHS Reference Costs
2017–201833)
EUA of rectum and manual
evacuation
£1100 ‘Minor anal procedure’. (NHS Reference Costs
2017–201833)
EUA of rectum and evacuation
of haematoma
£1100 ‘Minor anal procedure’. (NHS Reference Costs
2017–201833)
Insertion of temporary SNS £3692 £680 temporary device cost (Hounsome and
Roukas32)
£1819 insertion of neurostimulator for treatment of
faecal incontinence, day case (FF47Z) (NHS Reference
Costs 2017–201833)
£1193 insertion of neurostimulator electrodes for
treatment of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
Insertion of permanent SNS £10,762 £7750 permanent device cost (Hounsome and
Roukas32)
£1819 insertion of neurostimulator for treatment of
faecal incontinence, day case (FF47Z) (NHS Reference
Costs 2017–201833)
£1193 Insertion of neurostimulator electrodes for
treatment of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
Laparoscopic insertion of
pudendal nerve stimulator
£10,762 £7750 permanent device cost (Hounsome and
Roukas32)
£1819 insertion of neurostimulator for treatment of
faecal incontinence, day case (FF47Z) (NHS Reference
Costs 2017–201833)
£1193 insertion of neurostimulator electrodes for
treatment of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
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prices) Source and assumptions
Inflated
from year
Laparoscopic sigmoid colectomy £13,851 Colectomy
£9218 complex large intestine procedures, ≥ 19 years,
with CC score 3–5 (FF31C) (NHS Reference Costs
2017–201833)
Ileoanal pouch formation/reversal of ileostomy
£4633 major small intestine procedures, ≥ 19 years,




£1300 Major anal procedures, ≥ 19 years, with CC score 0
(FF40B) (NHS Reference Costs 2017–201833)
Physiotherapy £57 Physiotherapist, adult, one to one, allied health
professionals, community health services (A08A1)
(NHS Reference Costs 2017–201833)
Posterior tibial nerve stimulation £2579 Hounsome and Roukas32
Rectal irrigation £76.28 NICE54
Removal of FENIX £1819 Insertion of neurostimulator for treatment of faecal
incontinence, day case (FF47Z) (NHS Reference Costs
2017–201833) (Assumed same as SNS)
Replacement of SNS wire £1193 Insertion of neurostimulator electrodes for
treatment of faecal incontinence, day case (FF47Z)
(NHS Reference Costs 2017–201833)
N/A
Sigmoidoscopy £402 Diagnostic flexible sigmoidoscopy, ≥ 19 years, day
case (FE35Z) (NHS Reference Costs 2017–201833)
Stoma £13,851 Colectomy
£9218 complex large intestine procedures, ≥ 19 years,
with CC score 3–5 (FF31C) (NHS Reference Costs
2017–201833)
Ileoanal pouch formation/reversal of ileostomy
£4633 major small intestine procedures, ≥ 19 years,
with CC score 0–1 (FF22D) (NHS Reference Costs
2017–201833)
Annual ongoing stoma care £2444 NICE55 2014–15
Wound closed up £967 Non-elective short stay (WH07D): infection or other
complications of procedures, with single interventions,
with CC score 0–1 (NHS Reference Costs 2017–201833)
Excluded as unrelated to FI and the interventions
Bilateral foot surgery





Right total knee replacement
CC, complexity and comorbidity; EUA, examination under anaesthetic; N/A, not applicable.
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prices) Source and assumptions
Abena pads £10.40 Pack of 30, premium Abena Abri-San-7–premium. URL: www.allabout
incontinence.co.uk/incontinence-brands/abena/abena-abri-san
(accessed 12 February 2021)
Adcal £2.95 Adcal-D3 750-mg/200-unit caplets (Kyowa Kirin Ltd, Galashiels, UK),
112 tablets (BNF42)
Alendronic acid £1.59 Alendronic acid 10-mg tablets (AAH Pharmaceuticals Ltd, Coventry, UK).
28 tablets (BNF42)
Alverine citrate £3.60 Alverine 60-mg capsule (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Amitriptyline (10 mg) £0.91 Amitriptyline 10-mg tablets (AAH Pharmaceuticals Ltd) 28 tablets
(BNF42)
Amitriptyline (25 mg) £0.72 Amitriptyline 25-mg tablets (AAH Pharmaceuticals Ltd) 28 tablets (BNF42)




Andrews Original Salts £5.49 250mg. URL: www.boots.com/andrews-original-salts-250g-10007017
(accessed 1 February 2019)
Aqua flush £33.95 URL: www.bcapformulary.nhs.uk/2118-trans-anal-irrigation-systems
(accessed 1 February 2019)
Aspirin (75 mg) £1.13 Aspirin 75-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Atorvastatin (20 mg) £0.78 Atorvastatin 20 mg (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Braltus® £25.80 Braltus 10-mg inhalation powder capsules with Zonda inhaler
(Teva UK Ltd, Castleford, UK). 30 capsules (BNF42)
Buscopan (10 mg) £3.00 Buscopan 10-mg tablets (Sanofi, Reading, UK). Hyoscine butylbromide
10mg. 56 tablets (BNF42)
Colpermin £3.77 Colpermin gastro-resistant modified-release capsules (McNeil
Products Ltd, High Wycome, UK). Peppermint oil 200 µl,
20 capsules (BNF42)
Candesartan (2 mg) £2.02 Candesartan 2-mg tablets (AAH Pharmaceuticals Ltd). Candesartan
cilexetil 2 mg. 7 tablets (BNF42)
Cefalexin £1.57 Cefalexin 250-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Celluvisic® dry eye drops £4.80 Celluvisic 0.5% eye drops 0.4-ml unit dose (Allergan Ltd, Marlow, UK).
Carmellose sodium 5mg per 1 ml. 30 unit dose (BNF42)
Cetirizine £0.81 Cetirizine 10-mg tablets. Cetirizine hydrochloride 10mg (BNF42)
Cholestyramine £10.76 Questran 4-g oral powder sachets (Bristol-Myers Squibb Pharmaceuticals
Ltd, Uxbridge, UK). Colestyramine anhydrous 4 g (BNF42)
Cinnarizine £5.06 Cinnarizine 15-mg tablets (AAH Pharmaceuticals Ltd). Cinnarizine
15mg. 84 tablets (BNF42)
Ciprofloxacin £2.11 Ciprofloxacin 100-mg tablets [Alliance Healthcare (Distribution) Ltd,
Chessington, UK]. Ciprofloxacin hydrochloride 100 g. 6 tablets (BNF42)
Citalopram (20 mg) £1.00 Citalopram 20-mg tablets (AAH Pharmaceuticals Ltd). Citalopram
hydrochloride. 28 tablets (BNF42)
Clindamycin £3.45 Clindamycin 150-mg capsules (AAH Pharmaceuticals Ltd). Clindamycin
hydrochloride 150mg. 24 capsules (BNF42)
Clonidine (25 mg) £4.50 Clonidine 25-mg tablets (AAH Pharmaceuticals Ltd). Clonidine
hydrochloride 25mg. 112 tablets (BNF42)
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prices) Source and assumptions
Co-amoxiclav £1.77 Co-amoxiclav 250-mg/125-mg tablets (AAH Pharmaceuticals Ltd).
Amoxicillin (as amoxicillin trihydrate) 250 mg, Clavulanic acid
(as potassium clavulanate) 125 mg. 21 tablets (BNF42). Co-codamol
Co-codamol (30 mg) £3.90 Co-codamol 30-mg/500-mg caplets (AAH Pharmaceuticals Ltd).
30 tablets (BNF42)
Codeine £0.74 Codeine 15-mg tablets (AAH Pharmaceuticals Ltd). Codeine phosphate
15 mg. 28 tablets (BNF42)
Co-dydramol
(10 mg/500 mg)
£0.71 Co-dydramol 10-mg/500-mg tablets (AAH Pharmaceuticals Ltd).
30 tablets (BNF42)
Colecalciferol (1.5 mg) £3.65 Adcal-D3 lemon chewable tablets (Kyowa Kirin Ltd). Calcium
carbonate 1.5 g, colecalciferol 400 unit. 56 tablets (BNF42)
Colestyramine £10.76 Questran 4-g oral powder sachets (Bristol-Myers Squibb
Pharmaceuticals Ltd). 50 sachets (BNF42)
Colpermin £3.77 Colpermin gastro-resistant modified release capsules (McNeil
Products Ltd). Peppermint oil 200 µl. 20 capsules (BNF42)
Coloplast anal catheters £76.28 NICE54
Cream for piles £2.49 Anusol® HC ointment (Church & Dwight UK Ltd, Folkestone, UK).
30 g (BNF42)
Peristeen irrigation £76.28 NICE54
Dioctyl £2.09 Dioctyl 100-mg capsules (UCB Pharma Ltd, Slough, UK). Docusate
sodium 100mg. 30 capsules (BNF42)
Doxycycline £17.30 Periostat® 20-mg tablets (Alliance Pharmaceuticals Ltd). 56 tablets (BNF42)
Dulcolax® £2.35 Dulcolax 10-mg suppositories (Sanofi). 12 suppository (BNF42)
Entrolax £2.35 Dulcolax 10-mg suppositories (Sanofi). 12 suppository (BNF42)
Estradiol pessaries
(10 mg)
£16.72 Vagifem® 10-mg vaginal tablets (Novo Nordisk Ltd, Gatwick, UK).
24 pessary (BNF42)






£1.72 Brand cost not found: assumed same as Lofric Sense. URL: www.
supplychain.nhs.uk/savings/price-ranking/∼/media/Files/Price%
20Ranking/Price%20Ranking%20Urology%20March%202018.ashx
(accessed 1 February 2019)
Flucloxacillin £1.00 Flucloxacillin 250-mg capsules (AAH Pharmaceuticals Ltd)
28 capsules (BNF42)
Fluoxetine (40 g) £1.80 Fluoxetine 40-mg capsules [Alliance Healthcare (Distribution) Ltd].
30 capsules (BNF42)
Folic acid £2.93 Folic acid 400-µg tablets (Phoenix Healthcare Distribution Ltd,
Runcorn, UK). 90 tablets (BNF42)
Furosemide (20 mg) £2.10 Furosemide 20-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Fybogel £2.73 Fybogel 3.5-g effervescent granules sachets plain SF [Reckitt
Benckiser Healthcare (UK) Ltd, Slough, UK]. 30 sachets (BNF42)
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prices) Source and assumptions
GAVISCON® £4.46 GAVISCON Advance Mint chewable tablets [Reckitt Benckiser
Healthcare (UK) Ltd]. 24 tablets (BNF42)
Glycerin suppositories £1.04 Glycerol 1-g suppositories (DE Pharmaceuticals, Prudhoe, UK).
12 suppository (BNF42)
Ibuprofen £3.60 Ibuprofen 600-mg tablets (AAH Pharmaceuticals Ltd). 84 packets (BNF42)
ICaps® £13.49 30 tablets URL: www.boots.com/icaps-extra-lutein-tablets-30s-10114811
(accessed 1 February 2019)
IMODIUM® £4.21 IMODIUM plus caplets (McNeil Products Ltd). 12 tablets (BNF42)
IMODIUM £1.17 IMODIUM 1-mg/5-ml oral solution (Janssen–Cilag Ltd, High
Wycombe, UK). 100 ml (BNF42)
Infliximab £377.00 FLIXABI® 100-mg powder for concentrate for solution for infusion vials
(Biogen Idec Ltd, Maidenhead, UK). Infliximab 100mg. 1 vial (BNF42)
Infliximab+ B12 injection £14.50 Cytamen 1000-µg/1-ml solution for injection ampoules (RPH





relief-tablets-6–5mg-60032265 (accessed 1 February 2019)
Lactulose £2.28 Lactulose 3.1–3.7-g/5-ml oral solution (Phoenix Healthcare
Distribution Ltd). 500 ml. (BNF42)
Lansoprazole £0.65 Lansoprazole 15-mg gastro-resistant capsules (AAH Pharmaceuticals
Ltd). 28 capsules (BNF42)
Lascido® £2.63 Macrogol compound oral powder sachets sugar free [Alliance
Healthcare (Distribution) Ltd]. 20 sachets (BNF42)
Laxicol® £2.63 Macrogol compound oral powder sachets sugar free [Alliance
Healthcare (Distribution) Ltd]. 20 sachets (BNF42)
Laxido® £2.63 Macrogol compound oral powder sachets sugar free [Alliance
Healthcare (Distribution) Ltd]. 20 sachets (BNF42)
Laxiolo® £2.63 Macrogol compound oral powder sachets sugar free [Alliance
Healthcare (Distribution) Ltd]. 20 sachets (BNF42)
Laxulo® £2.63 Macrogol compound oral powder sachets sugar free [Alliance
Healthcare (Distribution) Ltd]. 20 sachets (BNF42)
Lercanidipine (10 mg) £5.34 Lercanidipine 10-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets
(BNF42)
Levothyroxine (100 mg) £0.99 Levothryoxine sodium 100-µg tablets (AAH Pharmaceuticals Ltd).
28 tablets (BNF42)
Lisinopril £0.82 Lisinopril 2.5-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Loperamide £2.93 Loperamide 2-mg tablets (AAH Pharmaceuticals Ltd). 30 tablets.
30 tablets (BNF42)
Lactulose £2.28 Lactulose 3.1–3.7-g/5-ml oral solution (Phoenix Healthcare
Distribution Ltd). 500 ml. (BNF42)
Macrogol £2.63 Macrogol compound oral powder sachets sugar free [Alliance Healthcare
(Distribution) Ltd]. 20 sachets (BNF42)
Magnesium hydroxide £5.31 Magnesium hydroxide 7.45–8.35% oral suspension BP
(AAH Pharmaceuticals Ltd). 500 ml (BNF42)
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prices) Source and assumptions
MOVICOL® £5.41 MOVICOL oral powder 13.8-g sachets lemon and lime (Forum Health
Products Ltd, Redhill, UK). 20 sachets (BNF42)
Mebeverine £6.00 Mebeverine 135-mg tablets (AAH Pharmaceuticals Ltd).
100 tablets (BNF42)
Methocarbamol £12.65 Methocarbamol 750-mg tablets (AAH Pharmaceuticals Ltd).
100 tablets (BNF42)
Metronidazole (400 mg) £18.00 Metronidazole (AAH Pharmaceuticals Ltd). 21 tablets (BNF42)
Mini irrigation system £76.28 Assumed: NICE54
Mirabegron £29.00 Betmiga 25-mg modified-release tablets (Astellas Pharma Ltd,Woking, UK).
Mirabegron 25mg. 30 tablets (BNF42)
Movelat £8.39 Gel: 80 g URL: www.boots.com/movelat-relief-gel-80g-10023902
(accessed 1 February 2019)
MoviCell £25.55 Converted from Euros. URL: www.iafstore.com/uk/promopharma/
movicell-drena-plus-codp33303 (accessed 1 February 2019)
MOVICOL £8.11 MOVICOL chocolate oral powder 13.9-g sachets (Forum Health
Products Ltd). 30 sachets (BNF42)
Naproxen (500 mg) £12.00 Naproxen 500-mg tablets (AAH Pharmaceuticals Ltd)/28 tablets (BNF42)
Nitrofurantoin (500 mg) £15.42 Nitrofurantoin 50-mg capsules (AAH Pharmaceuticals Ltd).
30 capsules (BNF42)
Nortriptyline £8.55 Nortriptyline 10-mg tablets (AAH Pharmaceuticals Ltd).
30 tablets (BNF42)
Octasa (400 mg) £16.58 Octasa 400-mg MR gastro-resistant tablets (Tillotts Pharma UK Ltd,
Wellingore, UK). 90 tablets (BNF42)
Omacor (1000 mg) £6.00 Omega 3-acid-ethyl esters 1000-mg capsules (Glenmark Pharmaceuticals
Europe Ltd, Harrow, UK) 28 tablets (BNF42)
Omeprazole (10–40mg) £5.79 Omeprazole 20-mg gastro-resistant (AAH Pharmaceuticals Ltd).
28 tablets (BNF42)
OTC laxatives £1.00 Senna 7.5-mg tablets (AAH Pharmaceuticals Ltd). 20 tablets (BNF42)
Oxybutynin hydrochloride £3.05 Oxybutynin 2.5-mg tablets (AAH Pharmaceuticals Ltd). 56 tablets (BNF42)
Zapain® (500 mg) £3.85 Zapain 30-mg/500-mg capsules (Advanz Pharma, London, UK).
100 capsules (BNF42)
Pantoprazole £0.80 Pantoprazole 20-mg gastro-resistant tablets (AAH Pharmaceuticals Ltd).
28 tablets (BNF42)
Paracetamol £1.53 Paracetamol 500-mg caplets (AAH Pharmaceuticals Ltd).
100 tablets (BNF42)
Peristeen bowel wash £76.28 NICE54
Pregabalin £3.43 Pregabalin 25-mg capsules (AAH Pharmaceuticals Ltd). 56 capsules (BNF42)
Proctosedyl Ointment £10.34 Proctosedyl Ointment (Sanofi). 30 g (BNF42)
Procyclidine £3.47 Procyclidine 5-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets (BNF42)
Questran® powder £10.76 Questran 4-g oral powder sachets (Bristol-Myers Squibb
Pharmaceuticals Ltd). 50 sachets (BNF42)
Questran £10.76 Questran 4-g oral powder sachets (Bristol-Myers Squibb
Pharmaceuticals Ltd). 50 sachets (BNF42)
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prices) Source and assumptions





mini_system (accessed 1 February 2019) (includes 15 cones)
Ranitidine £1.50 Ranitidine 150-mg tablets (AAH Pharmaceuticals Ltd). 60 tablets (BNF42)
Replens MD™ Vaginal
Moisturiser
£11.49 Replens MD Vaginal Moisturiser: 35 g. URL: www.boots.com/replens-
md-vaginal-moisturiser-35g-10025232 (accessed 1 February 2019)
Senna £1.00 Senna 7.5-mg tablets (AAH Pharmaceuticals Ltd). 20 tablets (BNF42)
Senokot £3.23 Senokot Max Strength 15-mg tablets [Reckitt Benckiser Healthcare
(UK) Ltd] (BNF42)
Sertraline £0.76 Sertraline 50-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets
(BNF42)
Simvastatin £0.55 Simvastatin 10-mg tablets (AAH Pharmaceuticals Ltd) 28 tablets (BNF42)
Suppositories (generic) £3.49 URL: www.boots.com/boots-constipation-relief-12-suppositories-
10006837 (accessed 12 February 2021) (12 tablets)
Telmisartan £6.00 Telmisartan 20-mg tablets (AAH Pharmaceuticals Ltd). 28 tablets
(BNF42)
Thyroxine £1.20 Levothyroxine sodium 12.5-µg tablets (AAH Pharmaceuticals Ltd).
28 tablets (BNF42)
Trajenta £33.26 Trajenta 5-mg tablets (Boehringer Ingelheim Ltd, Bracknell, UK).
28 tablets (BNF42)
Tramadol £0.76 Tramadol 50-mg capsules (AAH Pharmaceuticals Ltd). 30 capsules (BNF42)
TRUSOPT® eye drops £6.33 TRUSOPT 20-mg/-ml eye drops (Santen UK Ltd, St Albans, UK). 5 ml
(BNF42)
Vitamineral Green £98.22 500 g. URL: www.amazon.co.uk/Healthforce-Vitamineral-Green-
Powder-500-Grams/dp/B001H0T4TA/ref=sr_1_fkmrnull_1?
keywords=vitamineral±green%26qid=1552578134%26s=gateway%
26sr=8–1-fkmrnull (accessed 1 February 2019)
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£95.47 Curtis and Burns56 estimates for costs/minute and




£37.00 Curtis and Burns56 estimates for a consultation duration of
9.22 minutes
2017
GP telephone/e-mail £28.40 Curtis and Burns56 estimates for costs/minutes and Curtis
and Burns57 lasting 7.1 minutes at a per patient contact time of
£4. Curtis and Burns57 estimates for duration. The same cost is
assumed for any values entered for telephone contacts in the
telephone contracts in the final column for all of ‘GP surgery




£38.45 ‘District nurse, adult, face to face’ (NHS Reference Costs
2017–201833) under community health services
District nurse
(telephone/e-mail)
£18.88 ‘District nurse, adult, none face to face’ (NHS Reference Costs
2017–201833) under community health services
GP out of hours
(face to face)
£124.06 Curtis and Burns56 estimates for travelling time costs/minute





£14.11 Curtis and Burns41 estimate per hour £54.60 (£42 × 1.30 ratio
for direct contact time). An average consultation of
15.5 minutes (PSSRU, 2014/2015)
Practice nurse
(telephone/e-mail)
£4.26 Curtis and Burns41 page 182 under ‘Time use of community
care professionals’ states that GP practice nurses dedicate









£33.06 ‘Physiotherapy, non-admitted non-face-to-face attendance,
follow-up’, using volume-weighted average of consultant-led










£43.64 ‘Occupational therapy, non-admitted none face-to-face
attendance, follow-up’, (consultant-led and non-consultant-led
reference cost identical) (NHS Reference Costs 2017–201833)
2016





£23.32 Assumed same ratio face to face: telephone as occupational
therapist (53%)
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prices) Source and assumptions
Inflated
from year
Other support from personal social services
Meals on wheels (frozen) £4.65 URL: www.leeds.gov.uk/adult-social-care/help-at-
home (accessed 3 April 2019). Assumed cost of
£3.65 for a main course and £1.00 for dessert
(uppermost values)
2018
Meals on wheels (hot) £8.80 URL: www.leeds.gov.uk/adult-social-care/help-at-
home (accessed 3 April 2019). £6.00 for the hot
main meal and dessert and a cost of £2.80 for
the tea
2018
Laundry services £14.00 URL: www.laundryheap.co.uk/ (accessed 3 April
2019). £14 per 6 kg wash
2018
Home help, face to face (assumed
same cost as that of cleaner, carer,
home care and health and social care)
£58.54 ‘Health visitor, other clinical interventions’
(NHS Reference Costs 2017–201833)
2017
Community and residential based services
Nursing home/hospice stay, per day £468.26 ‘Inpatient day in hospice care’ (Public Health
England, 2017)
2012
Convalescent care £158.00 Per day permanent resident week ‘Local
authority own-provision residential care for
older people (age 65+)’ from Curtis and Burns41
2017–18



















Total n 89 80 73 63 47 47 47 47
Mean 0.762 0.754 0.769 0.750 0.798 0.756 0.793 0.770
FENIX n 44 38 37 31 24 24 24 24
Mean 0.761 0.771 0.777 0.731 0.802 0.772 0.792 0.757
SNS n 45 42 36 32 23 23 23 23
Mean 0.763 0.738 0.760 0.768 0.794 0.740 0.794 0.783
Costs: health and social care
Total n 81 76 67 47 47 47 47
Mean £116.72 £126.34 £121.02 £103.95 £121.71 £142.50
FENIX n 39 38 32 24 24 24
Mean £107.70 £125.26 £176.15 £110.45 £128.64 £203.39
SNS n 42 38 35 23 23 23
Mean £125.10 £127.41 £70.62 £97.17 £114.48 £78.97
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Total n 94 92 91 47 47 47
Mean £416.83 £501.89 £131.52 £716.18 £464.17 £69.36
FENIX n 47 46 45 24 24 24
Mean £603.07 £847.81 £180.45 £954.11 £820.70 £86.13
SNS n 47 46 46 23 23 23
Mean £230.60 £155.97 £83.66 £467.91 £92.14 £51.87
Costs: medications
Total n 81 76 67 47 47 47
Mean £9.75 £7.52 £10.84 £8.60 £9.46 £12.87
FENIX n 39 38 32 24 24 24
Mean £10.75 £9.15 £20.22 £11.87 £12.77 £23.14
SNS n 42 38 35 23 23 23
Mean £8.81 £5.89 £2.27 £5.19 £6.00 £2.15
a Baseline costs were not used in this study.
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